Browse Month: June 2017

Pharma, Biotech and Medical-Device Sales Careers #ono #pharma

#biotech pharma jobs


Pharma, Biotech, Medical-Device Sales: Which Is for You?

Pharma, Biotech and Medical-Device Sales Careers

Salespeople s roles in the pharmaceutical, biotechnology and medical-device industries are closely related, but there are some key differences in what each of the three types of sales jobs entails, as well as in the skills and personalities necessary to succeed.

From differing levels of technical know-how to varying degrees of on-the-job autonomy, here s what to keep in mind before targeting one of the areas as a prospective salesperson.

Breaking into the Field

Although it is tough to get a sales job in any of the three areas, it s a little easier to break into the pharmaceutical industry than it is to break into biotech or medical devices, says Kerrie Espuga, who worked in pharmaceutical sales for 13 years before becoming managing director of New York City corporate training firm Corporate Trendsetters in 2008. That s because the pharmaceutical industry is bigger and generally employs more salespeople. Another reason is that the level of technological and scientific savvy required to be a top-notch salesperson is generally lowest for pharma, a little higher for biotech (which requires a thorough understanding of research using genetic engineering technology) and extremely high for medical devices.

When I was a sales manager conducting interviews for a pharmaceutical company, a candidate could have sold copiers for two years and could get the sales job if he had an excellent track record, Espuga says. Not so with biotech sales. Sometimes biotech mandates some kind of medical background or previous experience selling within the healthcare industry, she says. That s because biotech is a little more scientific, a little more technical, she notes.

Selling medical devices is even more complex than selling pharma or biotech products, according to Gil Carrara, MD, a partner in the biotechnology and healthcare practice at Battalia Winston Amrop, an executive search firm in New York City. Many times a device person will go right into the OR and work with the surgeons, Carrara says. They conduct simulations related to using the product, for example. You have to understand everything about the product, he says. That s why [medical-device sales reps] are usually PhDs or engineers.

Interestingly, sometimes employers recruiting medical-device sales reps reject people with pharma experience, because selling medical devices requires a much more direct approach than the more marketing-oriented approach pharma reps typically use, Espuga notes.

Choosing a Corporate Culture

The corporate cultures of pharmaceutical and biotech companies also differ. With a long history, the pharmaceutical industry is large and well-established. Biotech is a newer industry, poised for growth.

Since Big Pharma has been around for so long and is so established, they ve been successful in growing and growing and growing, Espuga explains. This means that several salespeople representing the same product often call on the same doctor, she says. However, biotech is more specialized and has fewer reps. It s not as saturated, so biotech reps have a little easier access to doctors because they re not [selling] me-too drugs, she says.

In recent years, jobs in the biotech industry may have been considered riskier and less stable than jobs in large pharmaceutical companies, but that perception has changed now that some of the biggest pharma firms have implemented layoffs. I think in this day and age, risk can be found anywhere, says Kelly Hammons, a product manager for pharma company US WorldMeds, who has worked in both pharmaceutical and medical-device sales. When considering a job selling a new product in biotech, Hammons says you should ask, Is the biotech a startup? Does the company have other stable drugs that will keep it afloat? Where is its funding coming from?

On the other hand, Espuga notes, a small biotech startup could perform so well that it gets acquired by one of the pharma or medical-device giants.

Team Player or More Autonomy?

Effective teamwork is important for pharmaceutical reps, Hammons says, while team building is often less emphasized for biotech and medical-device salespeople. Big Pharma needs to be consistent with its messaging, so if nine reps are running around with the same product, everyone needs to be on the same page, Espuga says. There is a lot of team building and camaraderie, because the goal is to form a synergistic team that trusts each other and does really well. Biotech and medical-device sales, on the other hand, are more entrepreneurial and more autonomous, she says. It s more like you re running your own little business.

The potential for six-figure sales salaries is one reason motivated and tenacious individuals pursue sales jobs in any of the three areas — pharma, biotech and medical devices. The potential for a salesperson to earn a blockbuster bonus is best in medical-device sales, followed by biotech and then pharmaceutical sales, Espuga says. It s a decision about what kind of culture you want. Do you want a team environment with a lot of support and camaraderie, or do you want autonomy and the possibility of making more dollars?

Related Articles

Dusa Pharma: Latest News – Videos, Photos about Dusa Pharma #m #pharma

#dusa pharma



Pharma headwinds here to stay, tread with caution

Seven pharma cos’ managements say pricing pressure and tightening regulatory noose worrisome in near term, but long-term outlook’s healthy.

1 Sep, 2016, 08.22AM IST

IT, pharma ultimately going to perform: Rakesh Jhunjhunwala

In IT and pharma, the first few names remain the same, but the order keeps changi.

30 Aug, 2016, 12.25PM IST

Pharma companies in race to acquire Zincovit, Zincofer

Leading pharma players Cadila Healthcare, Torrent Pharma and GSK Pharma are in a three.

29 Aug, 2016, 05.13PM IST

Buy Escorts and Sun Pharma: Experts

As the markets closed past week on the high, coming week is expected to perform better than the last. Experts suggest the stocks that can make news and earn investors good money in trade.

13 Aug, 2016, 01.53PM IST

Buy Escorts and Sun Pharma: Experts

As the markets closed past week on the high, coming week is expected to perform better than the last. Experts suggest the stocks that can make news and earn investors good money in trade.

13 Aug, 2016, 12.48PM IST

Stocks in news: Bharti Airtel, Sun Pharma

The Indian market is expected to open higher tracking positive trend seen in other Asian markets.

18 Aug, 2016, 08.59AM IST

India will be world power in pharma, says Jhunjhunwala; is it time to buy?

Jhunjhunwala continues to bet on the pharma sector and Aurobindo Pharma is his preferred pick, which has rallied a little over 6 per cent in last one year.

31 Aug, 2016, 10.16AM IST

Pharma cos offer freebies to doctors, violate code: MP

The CAG, in a report in 2015, criticised the Central Board of Direct Taxes for allowing promotional expenses by pharma companies as deductible expenses while calculating tax.

30 Aug, 2016, 05.04AM IST

Cadila, Torrent Pharma, GSK in race for top-selling multivitamin brand

Apex Labs pioneered the introduction of zinc-based formulations in the Indian market and the company’s flagship brand Zincovit is the brand leader in its segment with a 19% market share, according to the company website.

29 Aug, 2016, 04.06PM IST

All about stocks: SBI and Sun Pharma

After closing on the highs, markets are expected to open and perform better in the coming week. Watch this video to know the stocks that are expected to give good returns and prove to be safe bet for retail investors.

13 Aug, 2016, 09.19AM IST

USFDA issues warning letter to ex-Sun Pharma US facility

The Philadelphia plant is among the two facilities that Sun Pharma had sold to Frontida BioPharm in June this year, along with 15 products, for an undisclosed amount.

26 Aug, 2016, 06.25PM IST

Buy Aurobindo Pharma Ltd. target Rs 1170.0. Citigroup

The sharp reduction in net debt during the quarter was encouraging and Aurobindo Pharma remained Citigroup’s top pick in Indian pharma space.

25 Aug, 2016, 01.37PM IST

Torrent, Natco, Sun are top pharma picks: Nischal Maheshwari, Edelweiss Securities

One cannot be positive on the whole pharma sector. One has to be very, very stock specific

25 Aug, 2016, 09.54AM IST

With an aim of expansion, pharma companies like Lupin and Torrent eyeing overseas acquisition

They are scouting for niche manufacturing sites, promising experimental drugs, specialty firms in emerging markets and opportunities in the US, Europe or Japan.

25 Aug, 2016, 02.24AM IST

Betting on banks, cement and pharma: V Srivatsa, UTI MF

At this moment, we are focussing on the recovery of the domestic economy

24 Aug, 2016, 04.20PM IST

#LeanIn: Maternity Bill passed in RS, now women to get 6 months off

While India was rooting for PV Sindhu, Andhra Pradesh and Telangana were googling her caste

The wait is over: iPhone 7 is coming soon

Centre returns bill for 400 per cent hike in Delhi MLA salaries

Price war: Idea, Vodafone and Bharti Airtel to slash tariffs to compete with Reliance Jio

Can football help you build your portfolio?

‘No chance’ of returning to the family business, says Onida Group’s Sasha Mirchandani

Best 13-inch laptops of the year

How to permanently erase data from an Android device

An IAS officer got a call from PM Narendra Modi at 10 PM and this is what happened next

Smartphones which are compatiable with Reliance Jio

Digvijay Singh terms Kashmir ‘India-occupied Kashmir’

Reliance Jio data plan tariffs: All you want to know

Cyclical mutual funds: Running the relay of business cycles profitably

I spent my first salary on candies: Sunny Leone

5 smartphones likely to launch this week

US immigration debacle over, SRK takes selfies with fans at son’s film school

Air India Express turns profitable for the first time


Life Science Executive Search #international #pharma #jobs

#pharma executive


Life Sciences

Innovation, patient access and pricing are driving the transformation of the life sciences

This is a time of enormous disruption in the life sciences. New IP being generated and new entrants from the technology industry are accelerating the dawn of personalised medicine.

With a nearly constant stream of capital and emerging technologies, biotech start-ups have proliferated; investors and Big Pharma are chasing innovations; and drug approvals have hit record levels globally.

Talent acquisition has become a key indicator of future success, with well-funded early stage companies and global pharma companies competing on an increasingly level playing field.


The European pharmaceuticals market remains in a frustrating position as Europe’s fragmented nature becomes increasingly clear in the wake of the Eurozone crisis.

Ageing populations, growth in emerging markets, and a flood of new technologies should all have spurred growth in the European pharma market. But complex compliance requirements, cash strapped governments, and increasing regulation have reined in pharma’s growth in Europe.

Odgers Berndtson’s global Life Sciences Practice works with pharmaceutical, biotechnology, outsourcing and analytics companies to revitalise their leadership teams and secure growth in Europe and beyond.

Sankyo pharma #pharmaceutical #contract #manufacturer

#sankyo pharma



Daiichi Sankyo Co. Ltd
3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo
103-8426 Japan

Herb Pharm Pharma Kava 1 oz #acceleron #pharma

#pharma kava



Promotes Peaceful Relaxation. Reduces Stress Frustration.

40-drop dose contains 64 mg of kavalactones. Pharma Kava is prepared from the rhizome roots of Piper methysticum plants which are naturally grown in the South Pacific islands of Vanuatu.

Caution: US FDA advises that a potential risk of rare but severe liver injury may be associated with kava-containing dietary supplements. Ask a healthcare professional before use if you have or have had liver problems frequently use alcoholic beverages or are taking any medication. Stop use and see a doctor if you develop symptoms that may signal liver problems including jaundice (yellowing of the skin or whites of the eyes) and brown urine. Other nonspecific symptoms can include nausea vomiting light-colored stools unexplained tiredness weakness stomach or abdominal pain and loss of appetite. Not for use by persons under 18 years of age or by pregnant or breastfeeding women. Not for use with alcoholic beverages. Excessive use or use with products that cause drowsiness may impair your ability to operate a vehicle or heavy equipment. Use only as directed label.

Two or three times per day take 40 drops in a little water.

Supplement Facts

Directions for Use: Two or three times per day take 40 drops in a little water.

Other Directions: FDA advises that a potential risk of rare but severe liver injury may be associated with kava. Ask a healthcare professional before use if you have or have had liver problems frequently use alcoholic beverages or are taking any medication. Stop use and see a doctor if liver symptoms occur (unusual fatigue abdominal pain appetite loss dark urine pale stools yellow eyes or skin). Not for use by persons under 18 years of age or by pregnant or breastfeeding women. Do not take with alcoholic beverages. Excessive use may briefly impair ability to drive or operate machinery. Keep out of the reach of children.

Other Ingredients
Contains certified organic grain alcohol (83-93%) & Kava extractives.

Contains certified organic grain alcohol (83-93%) & Kava extractives.

Horizon Pharma Bids $3 Billion For Depomed #alkem #pharma

#horizon pharma


Ireland’s Horizon Pharma launches hostile, $3 billion bid for U.S. rival

Ireland s Horizon Pharma is bringing its $3 billion takeover offer for U.S. rival Depomed directly to the company s shareholders after being rebuffed in its attempts to negotiate with Depomed s management.

Horizon s HZNP hostile bid for Depomed DEPO . announced on Tuesday. values the Newark, Calif.-based specialty pharmaceutical company at $29.25 per share, which represents a 42% premium over Depomed s Monday closing price. Depomed s share price jumped nearly 40% on the news of Horizon s offer.

The Irish manufacturer of drugs to treat arthritis and other inflammatory diseases said in a press release that it made repeated attempts to enter into deal discussions with Depomed s management and board starting in March, only to have those advances and its takeover offer rejected. Depomed makes a range of pain treatments and products that treat conditions related to the central nervous system. Horizon believes the deal would increase sales for both companies products while the five different drugs Depomed currently has on the market would nearly double the size of Horizon s current portfolio.

The strategic and financial benefits of our proposal are highly compelling, Horizon CEO and chairman Timothy Walbert said in a statement. Walbert added that his company s proposal offers substantial long-term value for Depomed s shareholders, whom he encouraged to urge the Depomed board to enter deal discussions.

If the two companies are able to reach an agreement, it would represent the latest in a string of deals for Horizon, which paid $660 million for Vidara Therapeutics International last year and also acquired Hyperion Therapeutics for $1.1 billion earlier this year. The pharma industry in general has seen more than its share of dealmaking recently, with deal volume and value on the rise in the first quarter of 2015, led by mega-mergers such as AbbVie s ABBV $21 billion purchase of Pharmacyclics and Pfizer s PFE $17 billion acquisition of Hospira HSP .

UPDATE: Depomed responded to Horizon s unsolicited takeover proposal with a statement in which the company said its board unanimously determined that it was not in the best interests of Depomed or its shareholders to pursue [Horizon s proposal]. Depomed said the Horizon bid undervalues the company.

Ireland s Horizon Pharma is bringing its $3 billion takeover offer for U.S. rival Depomed directly to the company s shareholders after being rebuffed in its attempts to negotiate with Depomed s management.

Horizon s HZNP hostile bid for Depomed DEPO . announced on Tuesday. values the Newark, Calif.-based specialty pharmaceutical company at $29.25 per share, which represents a 42% premium over Depomed s Monday closing price. Depomed s share price jumped nearly 40% on the news of Horizon s offer.

The Irish manufacturer of drugs to treat arthritis and other inflammatory diseases said in a press release that it made repeated attempts to enter into deal discussions with Depomed s management and board starting in March, only to have those advances and its takeover offer rejected. Depomed makes a range of pain treatments and products that treat conditions related to the central nervous system. Horizon believes the deal would increase sales for both companies products while the five different drugs Depomed currently has on the market would nearly double the size of Horizon s current portfolio.

The strategic and financial benefits of our proposal are highly compelling, Horizon CEO and chairman Timothy Walbert said in a statement. Walbert added that his company s proposal offers substantial long-term value for Depomed s shareholders, whom he encouraged to urge the Depomed board to enter deal discussions.

If the two companies are able to reach an agreement, it would represent the latest in a string of deals for Horizon, which paid $660 million for Vidara Therapeutics International last year and also acquired Hyperion Therapeutics for $1.1 billion earlier this year. The pharma industry in general has seen more than its share of dealmaking recently, with deal volume and value on the rise in the first quarter of 2015, led by mega-mergers such as AbbVie s ABBV $21 billion purchase of Pharmacyclics and Pfizer s PFE $17 billion acquisition of Hospira HSP .

UPDATE: Depomed responded to Horizon s unsolicited takeover proposal with a statement in which the company said its board unanimously determined that it was not in the best interests of Depomed or its shareholders to pursue [Horizon s proposal]. Depomed said the Horizon bid undervalues the company.

Time Inc. All rights reserved. is a part of the network of sites.

2016 Time Inc. All rights reserved. is a part of the network of sites.

2016 Time Inc. All rights reserved. is a part of the network of sites.

Sign In

Want the Full Story?


Sun joins dermatology rush with $230M DUSA buyout #juice #pharma

#dusa pharma


Sun joins dermatology rush with $230M DUSA buyout

Dermatology is hot. Valeant Pharmaceuticals ($VRX) has been snapping up skin-remedy companies, including its recent $2.6 billion deal for Medicis. Novartis’ generics unit Sandoz agreed in May to buy U.S.-based Fougera Pharmaceuticals, to become the biggest player in dermatology generics.

Now, India-based Sun Pharmaceutical is joining the party. It’s buying U.S. drugmaker DUSA Pharmaceuticals for about $230 million, or $8 per share, a 38% premium to yesterday’s closing price. The key prizes: DUSA’s Levulan combination therapy, used to treat non-hyperkeratotic actinic keratoses, and BLU-U, used to treat acne.

“DUSA has proven technical capabilities in photodynamic skin treatments, with USFDA approved manufacturing,” Sun Managing Director Dilip Shanghvi said in a statement. “DUSA’s business brings us an entry into dermatological treatment devices, where we see good growth opportunities.”

Indeed, as ICICI Direct analyst Siddhant Khandekar told Reuters. dermatology “was the only area, a growing one, where Sun did not have products in the United States. Plus, DUSA’s business fits nicely with Tara Pharmaceutical, a majority-owned subsidiary that Sun is in the process of acquiring fully. “This acquisition will actually complement Taro’s existing business, which has a strong dermatology product range,” Khandekar said.

– see the release from Sun
– read the Reuters story

OxyContin s Deception Costs Firm $634M – CBS News #avalon #pharma

#perdue pharma


OxyContin’s Deception Costs Firm $634M

Two days after agreeing to pay states nearly $20 million for falsely marketing OxyContin, the drug’s maker, Perdue Pharma, and three current and former executives plead guilty to federal charges.

The Stamford, Conn.-based maker of the powerful painkiller, and three of its current and former executives, pleaded guilty Thursday to misleading the public about OxyContin’s risk of addiction, a federal prosecutor and the company said.

Purdue Pharma L.P. its president, top lawyer and former chief medical officer will pay $634.5 million in fines for claiming the drug was less addictive and less subject to abuse than other pain medications, U.S. Attorney John Brownlee said in a news release.

The plea agreement comes after the company agreed to pay $19.5 million to 26 states and the District of Columbia to settle complaints that it encouraged physicians to overprescribe OxyContin.

For six million Americans a year, OxyContin is the prescription painkiller of choice, CBS News correspondent Bob Orr reports. But it’s also a highly addictive and deadly pill the favorite narcotic of drug abusers.

More than 400 deaths have been blamed on the drug, adds Orr. Now Purdue Pharma admits it lied to doctors and patients about the risks. to boost sales.

“With its OxyContin, Purdue unleashed a highly abusable, addictive, and potentially dangerous drug on an unsuspecting and unknowing public,” Brownlee said. “For these misrepresentations and crimes, Purdue and its executives have been brought to justice.”

Purdue learned from focus groups with physicians in 1995 that they were worried about the abuse potential of OxyContin. The company then gave false information to its sales representatives that the drug had less potential for addiction and abuse than other painkillers, the U.S. attorney said.

Even though the company was warned by health professionals, the media and members of its own sales force, “Perdue continued to push a fraudulent marketing campaign that promoted OxyContin as less addictive, less subject to abuse and less likely to cause withdrawal when they knew in fact that that was not true,” Brownlee told CBS News correspondent Barry Bagnato.

“People who are suffering from chronic pain want a drug that can relieve them of that pain and yet the same time is safe not only for themselves but for society,” Brownlee said. “And Perdue promised that.”

“Doctors are often approached right in their offices by pharmaceutical company sales reps dispensing information about one medication or another,” said CBS News medical correspondent Dr. Jon LaPook. “This case is a reminder to doctors not to believe everything they hear and to drug companies that the FDA will hold them accountable for fraudulent practices.”

Purdue Pharma said it accepted responsibility for its employees’ actions.

“During the past six years, we have implemented changes to our internal training, compliance and monitoring systems that seek to assure that similar events do not occur again,” the company said in a news release.

OxyContin, a trade name for oxycodone, is designed to have a time-released effect on a patient’s pain, but people who abuse the medication will crush the pills and then swallow, snort or inject the drug so that its pain-killing properties meant to be spread out over 12 hours are absorbed all at once.

From 1996 to 2001, the number of oxycodone-related deaths nationwide increased 400 percent while the annual number of OxyContin prescriptions increased nearly 20-fold, according to a report by the U.S. Drug Enforcement Administration. In 2002, the DEA said the drug caused 146 deaths and contributed to another 318.

“I think these people are drug pushers, just like street drug pushers,” said Joe Califano, the head of the National Center on Addiction and Substance Abuse and author of “High Society: How Substance Abuse Ravages America and What to Do About It.” “. It is outrageous that these people pushed this drug, addictive as they knew it was, onto the market and in effect damaged millions of innocent people.”

The drug became a major problem in Virginia particularly southwest Virginia and other areas of the Appalachian region, where it got the nickname “hillbilly heroin.”

In western Virginia, 228 people died from overdoses of oxycodone from 1996 to 2005, Brownlee said.

Brownlee said the guilty pleas were entered Thursday morning in U.S. District Court in Abingdon, about 135 miles south of Roanoke. In addition to Purdue’s plea, company chief executive officer Michael Friedman, general counsel Howard Udell and chief medical officer Paul Goldenheim each pleaded guilty to misdemeanor counts of misbranding the drug. They individually will pay fines totaling $34.5 million.

The fines will be distributed to state and federal law enforcement agencies, the federal government, federal and state Medicaid programs, a Virginia prescription monitoring program and individuals who had sued the company. At least $5 million will go toward a six-year company program to monitor compliance with the agreement.

2007 CBS Interactive Inc. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed. The Associated Press contributed to this report.

David Morgan is a senior editor at and

DUSA – News and Analysis – DUSA Pharmaceuticals, Inc #sun #pharma #products

#dusa pharma


DUSA is a vertically integrated dermatology company that is developing and marketing Levulan PDT and other products for common skin conditions. We operate in two segments, Photodynamic Therapy, or PDT, Drug and Device Products and Non-Photodynamic Therapy, or Non-PDT, Drug Products. Our Levulan® Kerastick® and BLU-U® products comprise our PDT segment, while Nicomide®, ClindaReach® and the other products acquired in the acquisition of Sirius comprise our Non-PDT segment. Our currently marketed products include among others Levulan® Kerastick® 20% Topical Solution with photodynamic therapy, the BLU-U® brand light source, and certain products acquired in the March 10, 2006 merger with Sirius Laboratories, Inc. including ClindaReach®.

Industry: Drug Manufacturers – Other

Country: United States

Dusa Pharmaceuticals (DUSA) reports preliminary results of Phase II clinical trials.

Dusa Pharmaceuticals (DUSA ) reports preliminary results of Phase II clinical trials investigating the use of the Levulan Kerastick in conjunction with BLU-U blue light illumination for the treatment of actinic keratoses of the face and scalp when utilizing short drug incubation. The study demonstrated that treatment after incubating for one, two or three hours resulted in a statistically significant number of patients with complete lesion clearance and a statistically significant reduction in AK lesion count.

Midday top 10 gainers: DUSA +38%. PRMW +23%. ARX +22%. RST +22%. ES +19%. FALC +18%. UPIP +18%.

11/08/12 • SA Editor Gaurav Batavia

• SA Editor Gaurav Batavia

Endo Pharma to withdraw application for new opioid painkiller formulation #pharmaceutical #formulations

#endo pharma


Endo Pharma to withdraw application for new opioid painkiller formulation

Endo Pharmaceuticals PLC has decided to withdraw its supplemental new drug application for the extended-release version of its Opana opiod painkiller but said it would continue to work with the U.S. Food and Drug Administration to advance the drug.

Shares in the company ENDP, -2.03% added 2.4% to $23.55 in premarket trading.

The pharmaceutical company, which is domiciled in Dublin and has U.S. headquarters in Malvern, Pa. plans to continue collecting and analyzing data on the drug and could refile.

“We anticipate the generation of additional data, and we will seek collaboration with FDA to appropriately advance Opana ER,” said Dr. Sue Hall, global head of research and development and quality at Endo.

Opana ER, one of Endo’s biggest selling brand-name drugs, has been facing generic competition. During the first quarter, sales of Opana ER declined 4.7% to $44.7 million and comprised roughly 14% of Endo’s U.S. branded drug revenue and a third of sales in its pain-management segment.

Copyright 2016 MarketWatch, Inc. All rights reserved.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. Intraday data delayed per exchange requirements. S P/Dow Jones Indices (SM) from Dow Jones Company, Inc. All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S P/Dow Jones Indices (SM) from Dow Jones Company, Inc. SEHK intraday data is provided by SIX Financial Information and is at least 60-minutes delayed. All quotes are in local exchange time.





No results found


Sponsored Message Five Points On How the Pharmaceutical Industry Creates Middle Class Jobs #pharmaceutical #industry

#jobs pharmaceutical industry


Create a Free TPM account

Reset Your Password

[Sponsored Message] Five Points On How the Pharmaceutical Industry Creates Middle Class Jobs

The pharmaceutical industry supports 50,000 trucking jobs and other supply line jobs that contribute $30B annually to the U.S. economy

Jobs in trucking, construction and manufacturing are the foundations of the American middle class, and the pharmaceutical industry employs tens of thousands of workers who build the facilities where drugs are made, help manufacture treatments and packaging, and drive across the highways of America to bring these life-saving medicines to local drug stores. In addition to 50,000 trucking jobs, the industry also supports 93,000 building services jobs, 6,000 manufacturing jobs, and 12,000 jobs for professionals in the electricity field. Steven Mongiardo, Executive Director of Global Facilities Management at Merck, compared his job managing a pharmaceutical facility site in southern Pennsylvania to being the mayor of a city. “The site is a small city – we have roughly 10,000 workers working in 6 million square feet of facility space,” he said. These workers have high-quality jobs that are often unionized, adding more than $30 billion total in value to the U.S. economy while at the same time ensuring that life-saving medicines reach those who need them the most.

The pharmaceutical industry is creating vocational, skills-based jobs that pay good wages

Vocational, trade-based science, technology, engineering and math (STEM) jobs are a critical building block of the American economy. These jobs—which usually require an associate’s degree or some accredited post high school training—are some of the very jobs President Obama had in mind when he announced America’s College Promise in his 2015 State of the Union address, a plan to provide free community college education to all students. Pharmaceutical companies are one of the top employers of vocationally-based STEM jobs. One such job in this category is a lab technician, a professional who helps drug researchers collect data, maintain equipment and calculate results. Lab technicians are required to have an associate’s degree and earn an average of $40,000 a year. The number of lab tech jobs is expected to grow by almost 30% between 2012 and 2022, creating approximately 47,900 additional jobs.

The pharmaceutical industry is a tech and innovation leader, on par with Silicon Valley

America has long been the global innovation leader—the telephone, television, and the internet are just a few of thousands of U.S. inventions that have changed the world. When you think “innovation” in the 21st century, you might think of Silicon Valley icons such as Jack Dorsey or Elon Musk. But the biopharmaceutical sector actually supports many of the jobs that make America the world’s top innovation hub. Merck’s Mongiardo said that though the physical products are small in the pharmaceutical industry—vials, syringes, capsules/tablets etc.—the scale of what’s required to produce these products is “magnitudes larger.” Numerous software engineers work in the biopharmaceutical sector, writing programs that allow researchers to track clinical drug trials and their outcomes. The industry also employs many of the top Ph.Ds. in chemistry and biology, biostatisticians, and more. The industry is a magnet for the best and brightest STEM professionals globally, which ensures that America remains the most innovation-driven economy in the world.

The pharmaceutical industry recognizes union jobs

Throughout American history, organized labor has been key to ensuring that workers have safe conditions, good benefits, competitive wages, and more. The pharmaceutical industry recognizes that importance. The Pharmaceutical Industry Labor Management Association (PILMA) is a unique coalition of pharmaceutical industry companies and the unions that represent their workers. PILMA works to provide training to workers, organize conferences, and give tours of training facilities to industry professionals. PILMA, in that vein, represents uncommon cooperation between unionized workers and the industries that employ them. “We need highly-skilled tradesmen, more so than most industries,” Mongiardo says, adding that many of the building trades unions have the best vocational training programs that he has seen. And Allan Rhodes, a Testing and Balancing Instructor at the Sheet Metal Workers Local 19 union, emphasized that since manufacturing stainless steel (frequently used at pharmaceutical plants because of their need for extremely clean environments) is more complicated than regular steel, training is of utmost importance. “It’s an intense training program that even apprentices go through,” he said. “I think it’s at least two nights a week, just getting your feet wet.”

Pharmaceutical companies are helping educate tomorrow’s workforce

The U.S. is struggling to keep up with countries like China and India in science and math education. According to a recent report by the President’s Council of Advisors on Science and Technology, the U.S. will need to produce one million additional STEM graduates over the next decade to maintain its position as the world’s leader in science and technology innovation. To meet this critical national need, pharmaceutical companies have funded almost 100 initiatives to improve STEM education in the United States. Companies including GlaxoSmithKline, AstraZeneca, and Bayer USA sponsor events like the U.S. Science and Engineering Festival and support summer science camps. These initiatives aim to develop early interest in STEM careers among children—especially girls and minorities—and end the shortage of STEM professionals in the U.S.

Pharmaceutical Rep: Qualifications #horizon #pharma

#pharma reps


Pharmaceutical Rep


Having a strong science background is a good start for aspiring pharmaceutical sales representatives. But you’ll need more than that A-plus in organic chemistry or a double major in biochemistry and physics to make it in the world of pharma. There’s a whole host of skills you’ll need that you can’t pick up in a classroom or by burying your nose in a textbook.

As in any sales job, pharma reps must be enthusiastic and persuasive, goal-oriented, and team players. They must be likable. They should be able to talk about many different subjects (maybe a doctor will be persuaded to use their drug after an extensive chat about his golf game), be adept at conversation, and be able to juggle several relationships with the doctors in their region.

A key attribute of a successful pharma rep is also flexibility. Try as you might, you are not in control of your schedule, since you’re angling to find time to meet with doctors. Any time meetings are scheduled, chances are that doctors get tied up seeing patients or taking care of a medical emergency. Sometimes these meetings have to be postponed or canceled altogether. In other words, fill out your day planner in pencil, not pen (or, invest in a smartphone or laptop or tablet).

And, of course, pharmaceutical sales representatives must be well put together. Heck, you’ve got to look presentable, wear nice clothes, and have washed your hair that morning. You’re the soldier on the front line representing a multi-billion dollar pharmaceutical company, and you can’t do that if you show up wearing sweatpants with a mustard stain on them, a pair of flip-flops, and a ratty T-shirt.

You may be the stellar candidate for a pharmaceutical sales job, but if you’ve had your fair share of fender-benders and speeding tickets, you had better look elsewhere for your dream job. Since many pharmaceutical companies give you a company car to drive around for appointments, they check your driving record and car insurance policies to make sure they can trust you with that investment.

Kind of, Sort of, Semi-Related Careers:

College Profiles

We’ll help you find your true college match.

College Majors

Our crystal ball for each college major.


Shmoop Finance

Career Test and Advice Center

Plan your future. or at least your next step.

Famous Quotes

The who, what, where, when, and why of all your favorite quotes.


Go behind the scenes on all your favorite films.

2016 Shmoop University. All rights reserved. We speak tech

2016 Shmoop University. All rights reserved.

Logging out…

Logging out.

You’ve been inactive for a while, logging you out in a few seconds.

Job Listings – HudsonAlpha Institute for Biotechnology Jobs #contract #pharmaceutical #companies

#biotechnology jobs


View All Current Job Listings 9 Total Job(s).

Located in Cummings Research Park in Huntsville, Alabama, one of the world’s leading science and technology business parks, the 153-acre HudsonAlpha Biotech Campus has state-of-the-art buildings and infrastructure for its unique blend of nonprofit research scientists, educators, and commercially-oriented entrepreneurs, who share work-space and know-how across organizational boundaries. Since opening its doors in 2008, the HudsonAlpha Biotech campus is home to more than 27 associate companies.

Below is a list of the current openings located on the HudsonAlpha Biotech Campus. Click on filter to sort by company. Click on the job title to learn more about the position.

HudsonAlpha – Research Assistant II – Su Lab

Diatherix – Billing Assistant II

Diatherix – Clinical Assistant

Diatherix – Director, Health Plan and Payor Relations

Diatherix – Document Control/ QA Specialist

HudsonAlpha – Research Assistant I – Genomic Services Lab

HudsonAlpha – Research Assistant I – Myers Lab

HudsonAlpha – Research Assistant II – Genomic Services Lab

Isis Pharma changes name to Ionis Pharma #pharmaceuticals #industry

#isis pharma


From Isis Pharma to Ionis

Isis Pharmaceuticals has changed its name to Ionis Pharmaceuticals, the Carlsbad biotech company announced Friday. With the new name — free of any similarities to the widely used acronym for the Islamic State terrorist group, comes a new stock ticker — IONS.

That ticker goes into effect when trading opens on Dec. 22. The company is also getting a new website:

But it wasn’t just the unsavory association that caused Isis to become Ionis, (pronounced “eye-OH-nis”) said Stanley T. Crooke, the company’s chairman and chief executive. It was the potential problems the confusion could cause for Isis employees.

“It was on my mind,” Crooke said. “That’s the thing that really tipped me over to the decision to do it. Why expose any of the people in our company to any unnecessary difficulty, particularly when traveling or going to their neighbor’s house? Why have them be distracted by that?”

With that symbolic name change, the company hopes to put behind it a controversy it had no part in creating.

Isis the company was founded in 1989, long before the Islamic State. The name ultimately derived from Isis, the ancient Egyptian goddess of magic and healing, considered appropriate for a pharmaceutical company.

But people unfamiliar with these facts, or who simply didn’t like the coincidence that an English-language acronym for a terrorist group was the same as the company’s name, forced the change.

With that done, Crooke said Isis can get back to full-time attention to the drugs in development, especially those getting close to approval.

“What made sense is, if we were going to do it, let’s do it now, and get it behind us” Crooke said. “I firmly believe that Isis the terrorist group will come to be history at some point — but not this year. We’re a big, complicated story to begin with. I don’t want to spend time on the name, when I can focus on the three drugs in Phase 3, the technology and the pipeline and so on.”

That pipeline contains dozens of medicines for severe or rare diseases such as various cancers, diabetes, spinal muscular atrophy and cardiovascular diseases. The Phase 3 drugs are nusinersen, for spinal muscular atrophy; volanesorsen, for high triglycerides; and IONIS-TTRRx, for TTR cardiomyopathy amyloidosis.

These drugs work through the antisense technology pioneered by Ionis. This technology blocks diseases at the genetic level, by blocking or changing the production of proteins.

Antisense uses small RNA molecules designed to bind to and inactivate complementary sequences of messenger RNA,which carries instructions for making proteins from DNA out into the cell.

Only a few drugs developed by Isis have been approved for sale. The most important is Kynamro, a cardiovascular drug for those with a genetic disease that causes extremely high levels of cholesterol. Approved in January 2013, Kynamro is sold by the company’s partner Genzyme, a unit of Sanofi.

With many more drugs in clinical development, the company would rather have the news be about those drugs than an unrelated controversy, Crooke said.

The company made the right decision, said biotech watcher John McCamant, editor of the Berkeley-based Medical Technology Stock Letter.

“It was handled perfectly,” said McCamant, who has long followed the company and is a fan of its drug development portfolio.

“They just got caught (in the wave of bad publicity,” McCamant said. After the Paris and San Bernardino terrorist attacks, the company had to act.

“I think they made the right decision at the right time,” he said.

Isis’ name problem first surfaced about two years ago, Crooke said.

“I was on Mad Money when (Jim) Cramer asked me (about a name change) and I said no,” Crooke said. Since then, numerous discussions have been held, and the focus on a name change became intense over the last few months.

Plenty of outsiders offered advice to Isis about a new name, including companies with services to sell, Crooke said. But Isis decided to select a new name on its own. Employees offered various suggestions, and perhaps 10 to 15 names made it all the way to him for consideration.

Eventually, opinion seemed to coalesce around Ionis.

“It seemed to me that everybody came together and decided that Ionis was a nice-sounding, feeling name, as soon as someone hit on it,” Crooke said.

Ionis is an empty vessel name, Crooke said, without any inherent meaning other than what is created by what the company does. Patent and other checks indicated that the name was free of legal problems or unwanted associations.

However, the name has been used in other contexts. Ionis is “a level 53 NPC ,” (non-player character) according to a World of Warcraft fan page. And in another fantasy game, Final Fantasy XI, Ionis is a beneficial magic spell.

There’s also Ionis Education Group based in Paris; the Ionis Art Hotel on the island of Zakynthos, Greece; and Ionis International. provider of Pacific Rim intercultural business training programs.

None of these other uses have meaning in the pharmaceutical industry, nor do they have the Islamic State’s bad reputation.

The name change’s cost was minimal, about $200,000 or less, Crooke said.

Jobs in pharmaceutical companies #pharma #bio

#jobs in pharmaceutical companies



Pfizer Australia offers outstanding career opportunities within an organisation established as a premier employer of choice.

Pfizer Australia is recognised for its excellence across all aspects of the healthcare business. Be it sales and marketing, research and development or manufacturing, our professionals are engaged in an environment where their talents, skills and drive for achievement are constantly in demand. Our track record of outstanding success has been fuelled by the dedication and dynamic nature of our people.

Pfizer Australia is committed to the hiring, advancement and fair treatment of individuals without discrimination based on factors such as race, disability, sex, age, ethnic or national origin, religion, citizenship, family or marital status, political beliefs, sexual preference or other factors included in the Equal Employment Opportunity Legislation.

Our Pfizer Values have ensured that this statement is more than a legal obligation. It is a way of life and a business-driven philosophy.

We strongly believe that a diverse workforce fosters more creative and innovative thinking throughout the organisation. Creating an inclusive environment, where everyone is respected and valued, enables us to leverage our diversity as a business driver and strengthens our position as a global leader.

To this end, we are committed to taking positive steps – such as accessing diverse candidate pools or accommodating special needs – to make sure we find, hire and retain the best-qualified people with diverse backgrounds.

If you feel that you share our values – integrity, innovation, respect for people, customer focus, collaboration, leadership, performance and a sense of community – please approach us with interest in any of the career opportunities we are currently advertising.

We look forward to hearing from you.

Click here for current career opportunities with Pfizer Australia.

Glossary of Medicinal Chemistry #nutra #pharma #corp

#medicinal chemistry


International Union of Pure and Applied Chemistry
Chemistry and Human Health Division
Medicinal Chemistry Section


(IUPAC Recommendations 1998)

Prepared for publication by C.G. Wermuth 1 (Chairman), C.R. Ganellin 2. P. Lindberg 3 and L.A. Mitscher 4

1 Facult de Pharmacie, Universit Louis Pasteur, Strasbourg (France),
2 University College London, London (U.K.)
3 Astra H ssle AB, M lndal (Sweden)
4 School of Pharmacy, University of Kansas, Lawrence (Kansas, USA)

The definitions used in this glossary are identical to those in the published document, see Pure Appl. Chem.. 70. 1129-1143 (1998) [Copyright IUPAC; reproduced with the permission of IUPAC]. If you use any of these definitions please cite this reference as their source. For problems in converting the text into a World Wide Web version see the IUPAC home page.

A PDF of the document is available.

For Belorussian version see

Abstract: The objective of the glossary is to provide in a single document a consistent terminology and concise definitions of terms covering the various aspects of medicinal chemistry. This was felt necessary with regard to the rapid changes occuring in medicinal chemistry and also by the need to establish international definition standards. Effectively the possibility exists that in different countries certain terms may not have the same meaning, in such a case the creation of an internationally accepted definition is particularly justified.

A Working Party belonging to the IUPAC Section on Medicinal Chemistry has therefore been assembled which prepared the present glossary. Concise but sufficiently explanatory definitions have been formulated for about one hundred commonly employed terms which can be considered of particular interest to the medicinal chemistry community. The glossary has been compiled in part from definitions proposed by the Working Party in part from earlier IUPAC glossaries and in part from well-accepted definitions taken from the literature but which were sometimes published in journals or books that may not be readily accessible.


The glossary has been compiled in part from definitions proposed by the Working Party and in part from well-accepted definitions taken from the literature. In most cases, definitions given here are for specific areas of medicinal chemistry. Some definitions taken from the Glossary for Chemists of Terms Used in Biotechnology (Pure Appl. Chem.. 1992. 64. 143-168; (c) 1992 IUPAC) were also included, eventually in a slightly modified form; they are identified by an asterisk*. Others, which appear in the Glossary on Computational Drug Design (Pure Appl. Chem.. 1997. 69. 1137-1152) and in Glossary for Chemists of terms used in Toxicology (Pure Appl. Chem. 1993. 65. 2003-2122), are identified by a double** and a triple*** asterisk respectively.

FTC Sues Endo Pharmaceuticals Inc #top #biotech #companies #2013

#endo pharma


FTC Sues Endo Pharmaceuticals Inc. and Others for Illegally Blocking Lower-Cost Generic Versions of the Branded Drugs Opana ER and Lidoderm

The Federal Trade Commission filed a complaint in federal district court alleging that Endo Pharmaceuticals Inc. and several other drug companies violated antitrust laws by using pay-for-delay settlements to block consumers’ access to lower-cost generic versions of Opana ER and Lidoderm.

Following more than a decade of FTC challenges to pay-for-delay settlements, today’s enforcement action is the first FTC case challenging an agreement not to market an authorized generic – often called a “no-AG commitment” – as a form of reverse payment.

“Settlements between drug firms that include ‘no-AG commitments’ harm consumers twice – first by delaying the entry of generic drugs and then by preventing additional generic competition in the market following generic entry,” said FTC Chairwoman Edith Ramirez. “This lawsuit reflects the FTC’s commitment to stopping pay-for-delay agreements that inflate the prices of prescription drugs and harm competition, regardless of the form they take.”

The FTC’s complaint alleges that Endo paid the first generic companies that filed for FDA approval – Impax Laboratories, Inc. and Watson Laboratories, Inc. – to eliminate the risk of competition for Opana ER and Lidoderm, in violation of the Federal Trade Commission Act.

Opana ER is an extended-release opioid used to relieve moderate to severe pain. Lidoderm is a topical patch used to relieve pain associated with post-herpetic neuralgia, a complication of shingles.

Under federal law, the first generic applicant to challenge a branded pharmaceutical’s patent, referred to as the first filer, may be entitled to 180 days of exclusivity as against any other generic applicant upon final FDA approval. But a branded drug manufacturer is permitted to market an authorized generic version of its own brand product at any time, including during the 180 days after the first generic competitor enters the market. As the FTC has previously argued in amicus briefs, a no-AG commitment can be extremely valuable to the first-filer generic, because it ensures that this company will capture all generic sales and be able to charge higher prices during the exclusivity period.

The FTC is seeking a court judgment declaring that the defendants’ conduct violates the antitrust laws, ordering the companies to disgorge their ill-gotten gains, and permanently barring them from engaging in similar anticompetitive behavior in the future.

The complaint charges that:

  • In 2010, Endo and Impax illegally agreed that until January 2013, Endo would not compete by marketing an authorized generic version of Endo’s Opana ER. In exchange, Endo paid Impax more than $112 million, including $10 million under a development and co-promotion agreement signed during the same time period. Endo used this period of delay to transition patients to a new formulation of Opana ER, thereby maintaining its monopoly power even after Impax’s generic entry. In 2010, Opana ER sales in the United States exceeded $250 million.
  • In May 2012, Endo and its partners, Teikoku Seiyaku Co. Ltd. and Teikoku Pharma USA, Inc. illegally agreed with Watson Laboratories, Inc. that until September 2013, Watson would not compete with Endo and Teikoku by marketing a generic version of Endo’s Lidoderm patch. In exchange, Endo paid Watson hundreds of millions of dollars, including $96 million of free branded Lidoderm product that Endo and Teikoku gave to Watson. As a result, Endo illegally maintained its monopoly over Lidoderm. In 2012, Lidoderm sales in the United States approached $1 billion.
  • Endo and Watson illegally agreed that, for 7½ months after September 2013 (including the 180-day first-filer exclusivity period for which Watson was eligible), Endo would not compete by marketing an authorized generic version of Lidoderm. This agreement left Watson as the only generic version of Lidoderm on the market, substantially reducing competition and increasing prices for generic lidocaine patches. As a result, Watson made hundreds of millions of dollars more in generic Lidoderm sales.

The complaint also names Allergan plc, the parent company of Watson, and Endo International plc, the parent company of Endo Pharmaceuticals Inc.

With the complaint, the Commission also filed a stipulated order for permanent injunction against Teikoku Seiyaku Co. Ltd. and Teikoku Pharma USA, Inc. settling charges for those two defendants. Under the stipulated order, the Teikoku entities are prohibited for 20 years from engaging in certain types of reverse-payment agreements, including settlements containing no-AG commitments like those alleged in the complaint. The agreed-upon order preserves Teikoku’s ability to enter other types of settlement agreements in which the value transferred is unlikely to present antitrust concerns, such as those providing payment for saved future litigation expenses.

The Commission vote to file the complaint was 3-1, with Commissioner Maureen K. Ohlhausen voting no and issuing a dissenting statement in connection with this vote. The Commission vote to accept the Teikoku settlement was 4-0. The complaint was filed under seal in the U.S. District Court for the Eastern District of Pennsylvania on March 30, 2016.

NOTE: The Commission files a complaint when it has “reason to believe” that the law has been or is being violated and it appears to the Commission that a proceeding is in the public interest. The case will be decided by the court.

The Federal Trade Commission works to promote competition. and protect and educate consumers. You can learn more about how competition benefits consumers or file an antitrust complaint. Like the FTC on Facebook. follow us on Twitter. read our blogs and subscribe to press releases for the latest FTC news and resources.

Contact Information

Betsy Lordan
Office of Public Affairs

Biotech Jobs – Search Biotech Job Listings #jobs #in #the #pharmaceutical #industry

#biotechnology jobs


Biotech Jobs

Biotech Employment Information

Biotech Industry Overview

Biotech jobs blend engineering and technology with biology, genetics and biochemistry to come up with solutions to challenges in human and animal health, and to develop new crops, fuels, medicines and other products.

Jobs in biotech involve research where the characteristics of living things are modified for scientific purposes. Potential products are identified, tested, moved through regulatory approval, marketed and manufactured. A specialist combining a career in biotech with a second career focus such as compliance, sales or IT handles each of those steps.

Biotechnology jobs can touch many areas:

Biological technicians work on research lab tasks like setting up equipment, running tests and reporting results. In the lab, biochemists, bioengineers and biophysicists work on research and development projects.

Other biotech careers focus on products:

  • In a regulatory compliance job, you work to gain government approval of new products.
  • Biotech marketing jobs involve sales.
  • Bioinformatics jobs apply information technology to scientific discovery.
  • Medical scientist jobs focus on ways fight diseases.
  • Natural sciences manager jobs combine business and science.

Biotech Job Market

More firms are entering the biotechnology industry, creating new jobs for people interested in developing medicines, improving crops and finding alternative energy sources. But more students are opting to work in biotech as well, creating competition for jobs in biotechnology.

The federal government funds much of US biotech, so biotech employment is heavily influenced by federal budget decisions.

The Bureau of Labor Statistics (BLS) predicts that between 2010 and 2020:

  • Jobs for biological technicians will grow 14 percent.
  • Jobs for biochemists and biophysicists will grow 31 percent; however, that growth translates to only 7,700 jobs over the decade because the occupation is small.
  • Jobs for microbiologists will grow 13 percent.
  • Jobs for medical scientists will grow 36 percent, mostly in private industry.
  • Jobs for natural sciences managers will grow by just 8 percent due to outsourcing.

Biotech Salaries

Biotechnology salaries depend in large part upon how much education is required. According to the BLS, the 2011 median salaries for some common biotech jobs were:

  • Biological technician: $39,480
  • Microbiologist: $65,230
  • Medical scientist: $76,130
  • Biochemist and biophysicist: $79,230
  • Natural sciences manager: $114,770, which is among the highest biotech salary.

TransTech Pharma and Calithera Biosciences Enter Into Worldwide Licensing Agreement for Hexokinase II Inhibitor Program

#transtech pharma


TransTech Pharma and Calithera Biosciences Enter Into Worldwide Licensing Agreement for Hexokinase II Inhibitor Program

March 05, 2015 04:03 PM Eastern Standard Time

HIGH POINT, N.C.–( BUSINESS WIRE )–TransTech Pharma, LLC today announced a global licensing agreement granting Calithera Biosciences, Inc. exclusive world-wide rights to research, develop and commercialize TransTech’s portfolio of hexokinase II inhibitors. TransTech will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products.

Hexokinase II is the first enzyme in the pathway that enables cancer cells to convert glucose to energy and building blocks required for cancer cell growth. The Warburg effect describes the particular reliance of cancer cells on glycolysis for energy and tumor cell survival. FDG-PET imaging of cancer and diagnosis in the clinic exploits the Warburg effect by detection of increased uptake of a glucose analogue by cancer cells. Increased glycolysis has been posited to be an essential part of carcinogenesis, conferring a significant growth advantage as well as promoting typical tumor progression making it a new promising modality for treatment of cancer.

“We are excited to be partnering our hexokinase II program with Calithera. We selected Calithera because of their specific expertise and focus in tumor metabolism research and development and look forward to our continued partnership. This portfolio of hexokinase II inhibitors was discovered using our Translational Technology® which has also been utilized in the discovery of our other clinical and preclinical programs,” said Stephen L. Holcombe, President and CFO, TransTech Pharma, LLC.

About TransTech Pharma, LLC

TransTech Pharma, LLC is a privately held, clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. The Company’s high-throughput drug discovery platform, Translational Technology®, translates the functional modulation of human proteins into safe and effective medicines. TransTech Pharma, LLC has a pipeline of small-molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases, including Alzheimer’s disease, diabetes and other metabolic disorders, inflammation and oncology. For further company information, visit

About Calithera Biosciences, Inc.

Calithera Biosciences, Inc. (NASDAQ:CALA) is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, an orally bioavailable inhibitor of glutaminase, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. Calithera is headquartered in South San Francisco. For more information about Calithera, please visit


10 Best Freelance Biotechnology Jobs Online In September 2016 #eusa #pharma

#biotechnology jobs


Biotechnology Jobs

Hourly – Expert ($$$) – Est. Time: Less than 1 month, Less than 10 hrs/week – Posted

I need a person that specialize in Nano technology. I need convert certain compounds to the Nano size to become water soluble and to be more absorbable by humans. I need an outline how to do the processes and the equipment required. Example of a company doing what am trying to do. CBD NanoUltra CBD Nano Ultra is a water-based concentrate that can easily be added to any water-soluble product such as water and beverages. Through advanced physics and chemistry, Isodiol uses ion-sized nutrients (the size that can move through cells’ membranes) and cleverly encases them with water molecules. Due to this incredible technology, people have reported faster response times with great results. Nano-materials are tiny particles measured in nanometers, or billionths of a meter. Due to their incredibly small size, nano-particles ingested in food and water are fundamentally different and can move throughout the body in advanced ways. Experts on nanotechnology are virtually unanimous that nanoscale materials have the potential for health effects that are uniquely different from the same substances comprised of larger-sized molecules. Nano-materials are already being added to foods, supplements and cosmetics.

Hourly – Expert ($$$) – Est. Time: Less than 1 month, Less than 10 hrs/week – Posted

We are looking to formulate a liquid or shampoo combination that will kill flea eggs and larvae. Kills and repels fleas, ticks and mosquitoes- Repels biting flies. Kills lice. Formulation needs to be unique, containing proprietary blend of ingredients. Should be affective on cats and dogs. Ingredients should be all natural and kill fleas and ticks on contact. This website has a list of competitors including ingredients used. aid=598

Fixed-Price – Intermediate ($$) – Est. Budget: $2,000 – Posted

Looking for a young geneticist, biotechnologist or molecular biologist or bioinformatician or biostatistician to complete smart data entry in a custom genotyping db. Tasks to perform: 1. Public db search about SNPs population frequencies (Ancestral allele frequency) for different ethnicity 2. Publications data mining to determinate the SNPs interpretation (Risk allele) according to a specific metabolic need 3. Writing Gene function description in relationship to this specific metabolic need 4. Writing short SNPs descriptions according to the specific metabolic need. 400 SNPs. Job ready to start. Budget to be defined.

Hourly – Intermediate ($$) – Est. Time: 3 to 6 months, 10-30 hrs/week – Posted

Would like to find a consultant to help me create a new food product. These will be liquid nootropics. They will need to withstand high temperatures and will need to be very potent. We will also discuss the shelf life of them.

Hourly – Intermediate ($$) – Est. Time: 1 to 3 months, Less than 10 hrs/week – Posted

this is my concept. need help to create a patch with this drug, the patch will be then stuck on human skin which will have micro chip. as this drug when released on the skin will have the reading from the sweat. which will analize the alcohol level. the reading will be then communicated via micro chip to the mobile phone. i need help with the drug – like what will be the ration we need to have it on the patch what will be the patch made of c please check url for the futher information University of California, San Diego (UCSD) has recently created this

Hourly – Expert ($$$) – Est. Time: 1 to 3 months, Less than 10 hrs/week – Posted

I am interested in updating and adding to an existing medical device known as the NeuRx Diaphragmatic Pacing System (DPS). This system allows quadriplegics and persons with ALS to breathe independently of conventional mechanical ventilation. The DPS uses a fixed number of pulses per minute, which works well, but does not allow the user to experience fluid control over his or her speech pattern. My intent is to reengineer the electronic control box that regulates varying inputs and to incorporate a pressure sensor into it. This will allow the user to draw breaths as needed, rather than waiting for the next pulse. I am doing this for personal use only and have no plans or intent to bring thing to market.

Fixed-Price – Intermediate ($$) – Est. Budget: $150 – Posted

We are a small business R D company based in Alabama, USA. We need a graphic design expert who offers services to researchers for publication in scientific journals. We are in the process of submitting one to an Elsevier journal. For this, we have one figure that requires to be more artistic and telling. We have a sample figure with some initial ideas for augmentation listed in the uploaded PPT file (can also be downloaded from the link below). The sample image is in Slide 1 and related questions are also listed in Slide 2. PPT File Download Link: Would like to know thoughts on this? A sample you may create will be helpful to proceed with an order. Based on your feedback and sample processed image, we can provide the final figure. We need to get this all done i.e. sample and the possible final order by Aug 12. Look forward to your swift response.

Hourly – Expert ($$$) – Est. Time: Less than 1 month, Less than 10 hrs/week – Posted

We are a biotech startup working on a number of developments in the bioplastics industry and require experienced professionals with proven trajectory to provide consultancy.

Fixed-Price – Intermediate ($$) – Est. Budget: $18 – Posted

You should have previous writing experience and some academic knowledge of science and biotechnology topics. You will need to be able to refer to statistics in the writing (using text links, not footnotes).

Fixed-Price – Intermediate ($$) – Est. Budget: $100 – Posted

PFA the details. Word-count – 2000 – 3000 The research project is about the Copy Number variation of Carboxylesterase CES1 gene. Gene copy number variation, where different individuals have different numbers of the same gene, is an extensive source of variation between different individuals, with a higher mutation rate than single DNA nucleotides. The extent to which it contributes to disease susceptibility and recent human evolution is unclear. A recent study comparing genomes of different human populations across the world suggested that a copy number variation involving the CES1 (liver carboxylesterase 1) gene shows the largest difference in copy number between different populations. Liver carboxylesterase 1 is involved in the metabolism of cocaine, heroin and several pharmaceutical drugs, including glycovir (an anti-HIV1 drug), aspirin and dabigatran etexilate (an anticoagulant) involved in prevention of stroke in individuals with atrial fibrillation. Liver carboxylesterase 1 is also involved in the invasion of P.falciparum into the liver. Aims Objectives: 1. Develop a robust molecular genetic assay for CES1 copy number. 2. Predict and investigate the effect of copy number on gene structure and expression. 3. Predict and investigate the duplications between UK Caucasians and find the frequency of duplicated alleles. What I have done? I have designed PRT assays to measure the copy number of CES1 gene. You will find the principle of the PRT in the introduction. I have design two PRT assay including. cis_PRT and trans_PRT. Only cis_PRT has worked and measure the copy number precisely when I applied it on known copy number positive controls. trans_PRT did not work and I excluded it from the experiment. I have run the cis_PRT assay on 5 positive controls and 34 samples from UK Caucasians. I have found that 9 samples from UK Caucasians have duplications as shown in the result. 8 out of 9 have heterozygote duplication alleles, while one have homozygote duplication allele. What I want from you? In the result part, if you could calculate the frequency of duplications between UK Caucasians and also calculate the frequency of heterozygote duplication alleles and the frequency of homozygote duplication allele. If you could apply the Hardy-Weinberg equation to calculate the frequency of those duplications alleles and then write the DISCUSSION PART. Thank you.

Company Profile #pharma #blogs

#transtech pharma


vTv Therapeutics LLC (vTv) is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. Our mission is to advance clinical drug candidates discovered with our innovative technology into safe and effective medicines.

vTv has a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv’s product candidate pipeline, platform technology, scientific team and strategic collaborations have enabled it to become a fully integrated pharmaceutical company.

The company’s commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company’s major R D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology.

vTv is advancing several proprietary drug candidates. The company’s lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer’s disease. In a Phase 2 clinical trial in patients with mild to moderate Alzheimer’s disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo.

Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer’s disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification.

vTv is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator (“GKA”) for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients’ HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.

In addition to TTP488 and TTP399, the vTv pipeline includes:

• TTP273: the first orally available GLP1R agonist for the treatment of type 2 diabetes in Phase 2
• HPP593: a PPARδ agonist for the prevention of muscle weakness associated with prolonged mechanical ventilation and critical injury
• HPP737: a PDE4 inhibitor for inflammatory diseases
• HPP971: a Bach1 inhibitor in phase I being developed for inflammatory/immunology related diseases
• Pre-clinical Hexokinase II inhibitors targeting cancer metabolism

Transtech pharma #isis #pharma

#transtech pharma



Glucagon-like peptide-1 (GLP-1) is a member of the incretin family of neuroendocrine peptide hormones secreted from L-cells of the intestine in response to food ingestion. GLP-1 has multiple metabolic effects that are attractive for an anti-diabetic agent. A key function of GLP-1 is to activate its receptor, GLP-1R, on the pancreatic β-cell to enhance glucose-dependent insulin secretion. Additional positive metabolic benefits of GLP-1 include suppression of excessive glucagon production, decreased food intake, delayed gastric emptying and improvement of β-cell mass and function. Unfortunately, the rapid proteolysis of GLP-1 in blood limits its use as a therapeutic agent.

There are currently several marketed GLP-1 mimetics (biologic agents). These agents have demonstrated notable glucose lowering in addition to weight loss. However, their widespread use is hindered by the route of administration (injection), and by the high incidence of gastrointestinal side effects (nausea and vomiting).

TTP273 has been identified using TTP Translational Technology®, as an orally bioavailable, potent, non-peptide agonist of GLP-1R for the treatment of type 2 diabetes. This molecule is the second generation from our path-finder molecule TTP054, and it is anticipated to provide excellent glycemic control and an attractive safety profile for the treatment of type 2 diabetes.

Clinical Data

The first generation compound has shown robust effects on glycemic control in multiple studies in patients with T2DM not well controlled on metformin. This includes a recently-completed 12-week study in 187 patients with T2DM, where notable HbA1c lowering, in addition to a trend for weight loss, was observed. The incidence of gastrointestinal adverse events noted with treatment is very low, and similar to placebo, in every study to date.

The program candidate, TTP273, has shown robust glucose lowering in a 2-week multiple dose study in patients with T2DM. Same as TTP054, the incidence of gastrointestinal adverse events noted with TTP273 is also no different than placebo. TTP273 is in phase 2 clinical development.

About the LOGRA Study

The LOGRA Phase 2 study will evaluate TTP273, which would be an orally bioavailable, potent, non-peptide agonist of GLP-1R for the treatment of type 2 diabetes. This molecule is the second generation from a path-finder molecule TTP054, and it is anticipated to provide enhanced glycemic control, weight loss and an attractive safety profile for the treatment of Type 2 diabetes. The completed Phase 1b trial in TTP273 demonstrated robust effects on postprandial fasting glucose.

The LOGRA study is expected to read out in late-2016.

ISIS Pharmaceuticals #catalent #pharma

#isis pharma products


Important Message: Fakes & Counterfeit Goods being sold on
We want to make you aware that due to the popularity of Isis Pharmaceuticals we are seeing an increasing number of fake websites and counterfeit products being sold.

FAKE WEBSITE: Please do not purchase from this website or any products related to this website.

Consumer safety is our primary concern and counterfeit products can be very dangerous.
Found a Fake Website? Or a Seller of Counterfeit goods? Let us know!

Please read the ‘Verify Product’ page carefully and if you have any doubts or queries get in touch! Whether you believe that you may have purchased/received a counterfeit product, found a seller on wholesale sites or have come across a website imitating Isis Pharmaceuticals products, please let us know immediately by e-mailing us! We have a dedicated team ready to assist you. Any communications will be kept confidential.

  • Isis orals now available.
  • Isis orals now available.

Welcome to ISIS Pharmaceuticals

Isis pharmaceuticals has a rich heritage in pharmaceutical research and development that has helped place the company on the forefront of hormone replacement therapy. Our products use the principles of bioadhesion and high grade filtration to achieve controlled, sustained delivery of hormones and other compounds that are difficult to administer. Isis Pharmaceuticals products have been commercialized through partnerships and recognition in the pharmaceutical industry.We are now a focused drug development company that is set on being the pioneer of a new era of hormonal replacement for the elite athletes.

IMPORTANT: It has been brought to our attention there are currently counterfeit products claiming to be Isis on the market. We ask our customers to be careful and take into account all the measures that have been put in place on all our products. Shortly we will be adding a section on our site on how to spot the difference from a original and fake Isis product. Alternatively for now please verify your product with the verification code that has been provided. If you have any further concerns please do not hesitate to contact us.


Trenbolone enanthate is an androgenic/anabolic steroid (AA), is a potent agon.

Tri Deca is a enginereed time released multi ester nandrolone blend. The nand.

Multi-ester Androgenic blend

Promastren is a triple ester androgenic/anabolic steroid (AA), it is an extr.

Boldenone undecylenate is a derivative of testosterone with similar androgeni.

Nandrolone Phenyl Propionate

Nandrolone phenylpropionate is an injectable anabolic androgenic steroid. It.

Isis Pharma Unitone 4 Arbutin 30ml price in Egypt #pharma #regulatory #affairs

#isis pharma products


Isis Pharma Unitone 4 Arbutin 30ml

Unitone 4 α Arbutin reduces visibly pifmentation spots and helps to blend complexion. 1\. α Arbutin reduces the overproduction of melanin 2\. The ascorbic Acid reduces the preformed melanin and has andi radical properties Indications Melasma, Chloasma Active depigmentation cream Dosage Apply Unitone 4 a Arbutin once to twice a day on the areas to be treated during 3 months.

Product Details

  • The best price of Isis Pharma Unitone 4 Arbutin 30ml by Agzakhana in Egypt is 91 EGP
  • Available payment methods are
  • Delivery fees are 10 EGP. with delivery expected within 2-5 day(s)
  • The first appearance of this product was on Apr 17, 2014
  • Agzakhana’s Description

    Unitone 4 α Arbutin reduces visibly pifmentation spots and helps to blend complexion. 1. α Arbutin reduces the overproduction of melanin 2. The ascorbic Acid reduces the preformed melanin and has andi radical properties Indications Melasma, Chloasma Active depigmentation cream Dosage Apply Unitone 4 a Arbutin once to twice a day on the areas to be treated during 3 months.


    No reviews exist yet for this product.

    Home – Pharma Headhunter #market #research #companies

    #pharma headhunters


    pharma headhunter

    Pharma-Headhunter is the recruiter for permanent or interim solutions in the pharmaceutical / healthcare industry.

    Here you can find job opportunities in the occupational field “Quality Management ”, “Quality Assurance ”, Quality Control “Regulatory Affairs ” and “Pharmacovigilance ”.

    Experienced HR Managers and professionals build up the Pharma-Headhunter team. We coach and support you during the complete application process and beyond.

    Many enterprises do not advertise all vacancies and for this reason not all available positions are published on the Pharma-Headhunter website.

    If you do not find today a suitable job we recommend that you send us your complete application documents (application, CV, certificates, notice period and desired salary) by electronic mail mentioning the desired position.
    We will check your application in advance and contact you. Counting on your approval we will register your convincing application in a data base.

    As soon as we get a recruitment request we search for adequate candidates in this data base. This procedure increases your chances to find a suitable position.


    compleo AG
    Seinsheimstr. 12 B
    81245 Munich

    For more than 10 years we are now supporting healthcare companies successfully in all HR matters.

    Still the job ad is most important for attracting new employees. In the competition for the most talented people our online portal offers you a sector oriented platform. Find your future professionals and executives with your informative job advertisement.

    compleo AG is an independent international consulting company. As the name suggests, compleo “completes” your business know-how.

    Our main consultancy areas are HR Management, Change Management, Talent Management and Japan Business.

    Our Locations #aai #pharma

    #pharma packaging


    Our Locations

    Pharma Packaging Solutions is now located in Clinton, TN in a new state-of-the-art facility particularly well suited for pharmaceutical packaging. Our parent company, Carton Service, Inc. is located in Shelby, OH. Both locations are within a day’s drive of 75% of the US and make good logistical sense for our national and international customers.

    We encourage you to set up a visit to either one of our locations. This will allow you to see for yourself what we can do and how we can help your business grow.

    Here is what some of our current customers have to say about the plant tour:

    I wanted to say thank you for taking the time out of your schedules to provide [our representatives] with a more in-depth view of the folding carton industry. They both came back with not only a much better understanding of the process, but a strong respect for Carton Service’s operation and employees. Carton Service once again proved that we made the right decision in extending our partnership.

    Set up a tour today by e-mailing us or give us a call at 800.533.7744.

    Amgen soars after bagging Onyx Pharma in $ buyout deal #top #10 #pharmaceutical #companies

    #onyx pharma


    Amgen soars after bagging Onyx Pharma in $10.4B buyout deal

    Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder at the table.

    After starting out with an unsolicited $120-a-share offer for Onyx ($ONXX), the giant biopharma company settled on a final price of $125 a share–all of it to be paid in cash–valuing Onyx at $10.4 billion, or $9.7 billion net of cash. News of the impending buyout had been percolating all weekend long after The New York Times first reported Saturday morning that a deal was at hand.

    The final price says a lot about Onyx CEO Tony Coles’ record. He scored big with a deal to buy Proteolix and the blood cancer drug carfilzomib (Kyprolis) for $276 million in cash and $445 million in milestones–after the $170 million milestone for an early approval gave way to a final $80 million payoff on the FDA’s decision last summer. Coles also aggressively went after Bayer when Onyx laid claim to a portion of Stivarga, filing suit before winning a big chunk of the revenue.

    “The Onyx management team exits after having created substantial and dramatic value for its shareholders,” concluded ISI’s Mark Schoenebaum in a note to investors Saturday.

    Amgen came out looking pretty good as well. Its shares barreled up almost 10% on the news as analysts cheered a deal that could reignite the company’s growth.

    Amgen ($AMGN) apparently backed off its sweetened offer of $130 a share. A last-minute roadblock developed around Amgen’s reported demand to see late-stage data on Kyprolis. There’s no word whether Coles ever handed that over, and Reuters and Bloomberg have run conflicting accounts on that matter. But a reduced price appears to have been part of the final resolution of outstanding issues.

    The multibillion-dollar deal marks a coup for Amgen CEO Robert Bradway, who’s been executing a series of deals in an effort to broaden the big biotech’s product lines as well as its pipeline.

    “We believe that Amgen is strongly positioned to realize the full potential of Onyx’s portfolio and pipeline for the benefit of physicians and patients,” said Bradway in a statement. “Our acquisition follows a thorough due diligence process and is fully consistent with our strategy of advancing innovative medicines that address serious unmet medical needs. We expect this acquisition will accelerate growth and enhance value for Amgen shareholders.”

    Bradway took over as CEO back in May 2012. At that time the company had recently cut back on R D to focus on an ambitious late-stage pipeline assembled by Roger Perlmutter, before the then-R D chief was squeezed out. But the ex-investment banker still had plenty to prove, with an aging group of blockbusters facing generic competition. Now his record will depend quite a lot on how successfully Amgen capitalizes on this buyout.

    South San Francisco-based Onyx followed a well-defined M A script after Amgen went public with its initial offer–a 38% premium over the stock price at that time in June. The biotech rejected the number as far too small and then went out to try to start a bidding war. And despite the apparent interest of Pfizer ($PFE), AstraZeneca ($AZN), Novartis ($NVS) and others, no other firm offer hit the table. AstraZeneca was most recently identified as doing due diligence on the numbers.

    Onyx scored big when it gained an early approval of Kyprolis on midstage data. The new late-stage trial results are needed to secure and expand the global market for the drug, which analysts believe is likely to earn about $2 billion a year. Onyx also comarkets Nexavar with Bayer, which now finds itself partnered with Amgen. Onyx also has a 20% royalty stream coming in from Bayer’s Stivarga. And Pfizer has been pushing development of palbociclib, a promising cancer drug that emerged from a collaboration with Onyx that could eventually provide an 8% royalty to Amgen.

    The next step will see how many of Onyx’s 900 staffers will make the transition to Amgen. Typically in buyouts like these, the acquiring company makes deep cuts to help cover the cost of acquisition.

    – here’s the release

    Special Reports: Onyx Pharmaceuticals – Buyout Buzz: The most frequently cited takeover targets in biotech | Kyprolis – Top 20 orphan drugs by 2018

    Amgen to Buy Onyx for $10 #pharmaceutical #companies #in #chicago

    #onyx pharma


    Amgen to Buy Onyx for $10.4 Billion to Gain Cancer Drug

    Amgen Inc. agreed to buy Onyx Pharmaceuticals Inc. in a $10.4 billion transaction that gives Amgen access to a rapidly expanding cancer-drug market with a new product that offers sure revenue.

    Amgen will pay $125 a share for Onyx’s outstanding stock, the companies said in a statement yesterday. Net of estimated Onyx cash, the deal is worth $9.7 billion. Onyx’s Kyprolis, approved last year for a rare blood cancer, may spur more than $3 billion in revenue by 2021, according to analyst estimates compiled by Bloomberg. South San Francisco-based Onyx is now studying the medicine in an expanded group of patients.

    The accord mirrors recent deals in which drugmakers bought companies with one or two promising products, rather than attempting large mergers that come with whole pipelines or offer business synergies. Kyprolis fills a hole for Amgen in a product line that largely contains drugs to support rather than treat cancer patients, at a time when the oncology market is growing increasingly important as the U.S. population ages.

    “It’s a steal for Amgen,” said Ori Hershkovitz, a partner at Sphera Funds Management Ltd. a Tel Aviv-based health-care hedge fund that holds both Onyx and Amgen shares. “It has secured its long-term growth. Securing your long-term growth for $10 billion, I think you made a good acquisition.”

    Amgen rose 7.7 percent to $113.75 at 4 p.m. New York time, the biggest gainer in the Standard Poor’s 500 Index today. The stock had increased 34 percent in the last 12 months. Onyx gained 5.6 percent to $123.49.

    Next Transaction

    The next buyout within the drug industry may involve Alexion Pharmaceuticals Inc. another single-product company whose blood-disease treatment Soliris generated $1.1 billion in sales last year as one of the world’s most expensive medicines. Alexion engaged Goldman Sachs Group Inc. as an adviser as it prepared for a possible takeover offer from Roche Holding AG, people with knowledge of the matter said last month.

    Amgen’s deal for Onyx follows similar agreements featuring a small number of already-marketed or late-stage experimental drugs.

    Last year, for example, Bristol-Myers Squibb Co. bought Inhibitex Inc. and Amylin Pharmaceuticals to gain individual treatments for diabetes and hepatitis C. The chief executives for both Pfizer Inc. and Merck Co. have said this year that they prefer similar “bolt-ons,” rather than mergers that come with a slate of products.

    ‘Unique Opportunity’

    While Thousand Oaks, California-based Amgen has gained from its dominance of the anemia market, the company has been seeking products to expand its product portfolio in cancer. Eight late-stage medicines are in development that will generate clinical trial data over the next three years, Chief Executive Officer Robert Bradway said in February.

    Bradway said today Amgen wanted to get in early to tap an expected surge in the blood-cancer drug’s growth. “It’s at a point where we feel we can help maximize the full potential of the product,” he said on a conference call discussing the deal.

    The price for Onyx is 44 percent higher than the stock’s $86.82 value on June 28, before the discussions with Amgen were disclosed. The deal will be financed using $8.1 billion in bank loans and cash it has in the U.S. the companies said in the statement. Approved by both boards, the transaction should close in the fourth quarter, they said.

    The price “leaves some net present value on the table for Amgen shareholders, but still allows Onyx shareholders to enjoy a substantial premium,” said Mark Schoenebaum, an analyst with International Strategy Investment Group in New York. “In addition, Onyx management can exit after having created substantial value in a relatively short period of time.”

    Drug Data

    At the same time, the deal may signal that prices may be dropping for biotechnology generally, Schoenebaum said. Amgen and Onyx agreed to the $125-a-share price after an earlier offer of $130 fell apart, people familiar with the negotiations said previously. The parties couldn’t resolve a dispute about Onyx drug data, said one of the people. And other drugmakers didn’t step in with higher bids.

    The information Amgen was able to see was sufficient, Bradway said. “We reviewed the data, that are available to us, and our confidence is reflected in the price that we moved forward with the transaction with,” he said today.

    Onyx’s shares soared after the company announced Amgen’s original $120-a-share offer at the end of June. That signaled some investors expected competing offers. AstraZeneca Plc, Pfizer and Novartis AG expressed interest, Bloomberg reported in July.

    Schoenebaum questioned whether the lowered price meant companies were becoming more skeptical of valuations. “Is there price sensitivity out there?” he asked in an e-mail. “Why didn’t it go for more? The Onyx analysts all said originally this would go for $140 or $150.”

    Amgen’s Deals

    The Onyx acquisition will be Amgen’s largest after its 2001 purchase of Immunex Corp. for $16.8 billion, data compiled by Bloomberg show. Amgen’s next-largest deal was its 2005 acquisition of Abgenix Inc. for $2.21 billion.

    In addition to Kyprolis, Onyx sells Nexavar for liver and kidney cancer in partnership with Germany’s Bayer AG. Onyx generated $362 million in 2012 revenue, with 80 percent coming from Nexavar and the stomach-cancer treatment Stivarga. The company gets a 20 percent royalty on Stivarga from Bayer, which has said it expects the medicine to be a bestseller.

    Amgen’s top product is Enbrel, a rheumatoid arthritis treatment that sold $4.24 billion in 2012. Neulasta, an immune system booster for chemotherapy patients, sold $4.09 billion. Aranesp, which helps raise kidney failure and cancer patients’ red blood cell counts, sold $2.04 billion, followed by Epogen, which does the same, at $1.94 billion.

    Coles Impact

    Onyx CEO N. Anthony Coles joined the company in March 2008. Since taking over, the shares have increased fourfold.

    The purchase is the third-largest acquisition of a biotechnology company in the past three years, according to data compiled by Bloomberg. Since August 2010, 62 biotechnology deals valued at $50 million or more were announced, with an average disclosed price of $1.29 billion and an average premium of 55 percent, the data show.

    Sanofi’s 2011 purchase of rare-disease drugmaker Genzyme Corp. for $20.1 billion was the largest, followed by Gilead Sciences Inc.’s purchase of Pharmasset Inc. for $10.6 billion.

    Lazard Ltd. and Bank of America acted as financial advisers to Amgen, and Sullivan Cromwell were legal advisers. Centerview Partners were financial advisers to Onyx, and Goodwin Procter LLP were legal advisers.

    Before it’s here, it’s on the Bloomberg Terminal. LEARN MORE

    Recruiting Pharmaceutical Physicians: Only Medics #alembic #pharma

    #jobs in pharmaceuticals


    Pharmaceutical Physician Jobs

    Recruiting Physicians for Pharma

    Only Medics is a specialist international medical recruitment company that focuses exclusively on the recruitment of pharmaceutical physicians for pharmaceutical companies, biotechnology companies, Clinical Research Organisations (CROs) and Regulatory Authorities.

    We successfully recruit on both a contingent and retained basis on permanent positions as well as interim medical assignments. Our geographic reach is truly global and although our main focus is the European job market, we also recruit for pharmaceutical physician jobs in the US, Canada, Australia and Asia Pacific.

    Created in 2005, Only Medics was the first of its kind: a niche specialist recruitment organisation catering solely to the need of physicians. Since then, Only Medics has distinguished itself as the market-leader in its field recruiting for more than 90 european organisations including many of the ‘top 10’ pharma. Today Only Medics is established as the medical recruitment company of choice and has attained an exclusive or preferred supplier for many organisations from global pharma through medium and small-sized companies to start-up ventures, CROs, Biotech companies and national regulatory bodies.

    With first-hand experience of working in the pharmaceutical/CRO and recruitment sectors, we have a detailed understanding of jobs for pharmaceutical physicians.

    Candidates enjoy the organisation s sole focus on their market place and an unrivalled range of career options from across the continent and beyond. Furthermore we offer in-depth career analysis and active steps to better prepare for interview success.

    Clients are presented with the most highly sought-after local or international medical experts for their challenging positions. We submit well-prepared candidates who meet the recruitment brief and provide superior guarantee of interview success and fast assignment-to-completion times.

    Job searches on each of our specialist sector departments and jobs can be found through the links below:

    For more information about our services and the jobs that we can help with please Contact Us

    Our experienced consultants are available to speak to you confidentially about our services. To find out more information or to discuss any of our vacancies please call our consultant team.


    “As of today I have been in-post for 3 months (how time flies!) so I thought I’d just drop you a quick line to once again say thanks for your help and also to let you know how I’ve been getting on. As I’m sure you can imagine it’s still something of a whirlwind in terms of getting used to the variety of tasks that I’ve been involved in but I’m gradually finding my feet and things are beginning to make a bit more sense. I’m still thoroughly glad I made the move into the Pharmaceutical industry and very grateful for your help. Thanks again.” Medical Adviser, hired into a global pharmaceutical company.

    Sun Pharmaceuticals to sell some low priority Ranbaxy brands – The Economic Times #tris #pharma

    #sun pharma products


    Sun Pharmaceuticals to sell some low priority Ranbaxy brands

    MUMBAI: Drug maker Sun Pharmaceuticals has put on the block a bundle of Ranbaxy brands which are low priority in its domestic market strategy or which may overlap with its own products, top industry executives said.

    The country’s largest drug maker completed acquisition of Ranbaxy last year from its Japanese owner, Daiichi Sankyo. as part of a $4 billion all-stock deal. The Ranbaxy brands that Sun is looking to sell rake in about Rs 115 crore in annual sales and the company is expecting a valuation of about 2.5x or Rs 250-270 crore for them, they said.

    Sun declined to comment on the matter. The persons quoted earlier said the deal has been in the market for over two months but the response has been lukewarm as some drugs on offer are seeing declining sales.

    But the bigger hurdle to the deal being attractive, according to them, is that the products belong to a wide range of segments — from orthopedics, anti-infective, urology, oncology, respiratory, antidiabetes and dermatology. A broad product basket makes it tough for a single buyer to take a consolidated marketing approach, they said.

    Among the products on Sun’s sale list is Fortwin, a narcotic-based drug used to treat severe pain conditions. The drug generated Rs 35 crore revenue last year, down 30 per cent from the previous year, industry executives said.

    The government has tightened regulations on sale of drugs in this category, making it difficult for the distribution chain to store and maintain records, which is one of the reasons cited for the shrinking sales of the product. However, a few other brands that form part of the offer are showing strong growth. For instance, Romilast, which is used in respiratory conditions, and Mobiswift, a drug used to relieve muscle spasm, are showing an uptrend, executives said.

    Sun has also put up for sale Insucare, one of the many insulins in the market, according to one executive who said, “Insulin is heavily dominated by big multinationals and the product is fetching low margins.”

    Broadly, Ranbaxy’s brands in the cardiovascular and diabetes segment saw sales of Rs 21 crore last year, while orthopedic drugs brought in Rs 52 crore. Sale of drugs in the respiratory, urology, oncology and dermatology segments stood at Rs 19 crore, Rs 8 crore, Rs 9 crore and Rs 3.5 crore, respectively.

    Last week, the Competition Commission of India cleared Strides Shasun’s Rs 165-crore deal to acquire two divisions of Sun Pharma that deal in neurology products.

    According to market research agency AIOCD shows, the market size of India’s pharmaceutical industry on the basis of 12-month moving annual total (MAT) was nearly Rs 97,000 crore at the end of 2015. Sun topped the list of drug makers with sales of Rs 8,472 crore, or market share of 9.2 per cent, followed by Abbott and Cipla.

    Help us understand your experience with Share your feedback here.

    International Undergraduate Admission Requirements #washington #university #admission #requirements


    Iowa State University

    International Undergraduate Admission Requirements

    Below are the general admission requirements for international students. To view the admission requirements for freshman or transfer students, select the appropriate type from the right menu.

    Academic Requirements by Country

    Minimum performance requirements have been determined for students educated in most countries.

    If your country is not listed, please send us an email with the name of your country, whether you are applying as a freshman or transfer, and we will send you the admission requirements separately.

    English Proficiency Requirement

    For the purpose of applying for admission to Iowa State University, English may be considered your primary language only if you have been raised in an environment where English is the ONLY official language of your locality and nation, and English has been the primary language used in your home.

    Applicants whose primary language is not English must meet the English proficiency requirement by any one of the options listed below.

    Minimum Score or Grade Required

    PTE does not utilize institutional codes

    For international students transferring from a U.S. College: The English Proficiency Requirement can be waived if a student completed a course equivalent to Iowa State University’s English 150 or English 250 with a grade of B or better from an accredited US two-year or four-year college or university (note: grade must be earned prior to enrollment at Iowa State).

    Conditional Admission

    If you apply for conditional admission, you will be asked on the application form if you wish to apply for Iowa State’s Intensive English and Orientation Program (IEOP ). If you would like to enroll in IEOP, please answer “Yes” to that question. IEOP is a full-time English language training program that offers classes at the same time as our regular classes.

    If you meet the other admission requirements, a conditional admission letter for the bachelor’s program will be issued along with the I-20 for IEOP. Please note that you must pass one of the required English proficiency examinations before you can begin regular classes.

    If you prefer to improve your English proficiency on your own, please select “I do not meet this requirement yet or choose not to apply for IEOP.” Your application will be held until you can submit your official examination results.

    Attorney Steve Farese under fire for saying women are – good – at lying #steve


    Attorney Steve Farese under fire for saying women are good at lying

    MEMPHIS, Tenn. — Well known Memphis area attorney Steve Farese is under fire for comments he made during a rape trial.

    During closing statements for the Mark Giannini rape trial Farese said, “There’s always a reason behind a lie. People can be very good at lying. Women can be especially good at it because they’re the weaker sex and we, that’s what the books say, and we want to protect them and not have anyone take advantage of them. At least I do.”

    The jury is made up of nine women and three men.

    Memphis Area Women’s Council executive director Deborah Clubb calls Farese’s comments “absolutely despicable.”

    The comment is getting a lot of attention on social media.

    One person tweeted, “What a despicable thing to say. Steve Farese – you are a disgusting person.”

    Dana Brolley tweeted, This is disgusting, misogynistic, sexist behavior.”

    Giannini is charged with raping a woman who came to his home for a job interview in 2014.

    The 25-year-old woman told police she was drugged and raped at Giannini’s home when she was hired to clean his home in June of 2014.

    He owned an information technology firm at the time of the attack.

    He was also on the board for the Boys and Girls Club, the Memphis Botanic Garden and the Memphis Chamber of Commerce.

    Giannini is facing charges for two other rapes dating back to 2002, but the trial that begins Tuesday only covers the 2014 case.

    Detectives searched Giannini’s house and found drugs, guns, and other evidence from one of the alleged rapes.

    When arrested he was found with his passport, a small contact case with Viagra and a large sum of cash according to police.

    What a despicable thing to say. Steve Farese – you are a disgusting person.

    Typostrate – the typography and design blog and site with graphic inspirations, lettering, free fonts,



    Typostrate is a site about typography and design. On our site you can explore cool calligraphy stuff, handlettering artworks, graphic design inspirations, sign painting, letterpress, typo book reviews, specials like typography mugs or shirts, typography artists and much more. Every week we offer you the monday typography quotes, which give you a good start in the week, the video wednesday, which shows you the latest and most famous typography films, friday free font, where you can download a font for free and the weekend inspiration, where all followers and fans are invited to send their inspirations for. Typostrate has also a facebook account, where every day are posted at least three artworks after a special theme, an instagram account with street typography and inspirations in type and a pinterest account where you can find different typography themes and folders, to get inspired. You see that our mission is to take everyone on a journey through the world of typography. We believe that typography is not only made for specialists or as a niche product. Typography is an own unique and independent field, which is much more interesting than it seems. We show you what you can do with, the passion and power of typography. Typostrate is written by Christian Goldemann and Michael Zeller. Enjoy it!


    Typostrate ist eine Seite über Typografie und Design. Hier findet ihr eindrucksvolle Kalligrafie, handgeschriebene Kunstwerke, Grafik Design Inspirationen, Schildermaler, Buchdruck, Typo Bücher, Specials, wie Typografie Tassen und Shirts, Schriftkünstler und vieles mehr. Jede Woche zeigen wir Euch Montags typografische Sprichwörter, die Euch einen guten Start in die Woche bereiten sollen, den Video Mittwoch, der die neusten und bekanntesten Typo Filme beinhaltet, die Freitag gratis Schriftarten, die ihr kostenlos runterladen könnt und die Wochenend-Inspirationen, bei denen jeder, ob Follower oder Fan seine Arbeiten oder Inspirationen einschicken kann. Typostrate hat dazu noch einen Facebook Account, mit vielen neuen Inspirationen zu Künstlern und urbaner Typografie, einen Pinterest Account mit typografischen Themengebieten und einen Instagram Account mit Impressionen während unserer Reisen. Unserer Mission ist es Euch mitzunehmen auf eine Reise durch die Welt der Typografie. Wir glauben, dass Typografie nicht nur für Spezialisten und Grafikdesigner, gemacht ist, sondern für jeden der sich dafür interessiert. Wir zeigen Euch die Kraft und Leidenschaft von Typografie. Die Autoren von Typostrate sind Christian Goldemann und Michael Zeller.
    Viel Spass beim lesen!


    Typostrate es una web sobre tipografía y diseño. Aquí encontraréis caligrafía impactante, obras de arte escritas a mano, inspiraciones sobre diseño gráfico, rotulistas, impresión tipográfica, libros, productos especiales como tazas y camisetas sobre tipografía y muchas cosas más. Todas las semanas, los Lunes os enseñamos proverbios para que empecéis bien la semana, el Vídeo del Miércoles contiene los nuevos cortos sobre tipografía más conocidos, el Viernes os podéis descargar tipos de letra gratis y también tenemos las inspiraciones del fin de semana, a las que cualquiera, sea seguidor o fan, puede enviar sus trabajos o inspiraciones. Typostrate además tiene una cuenta en Facebook, con inspiraciones de artistas y tipografía urbana, una cuenta en Pinterest con áreas temáticas sobre tipografía y una cuenta en Instagram con impresiones de nuestros viajes. Nuestra misión es llevaros con nosotros en nuestro viaje a través del mundo de la tipografía. Creemos, que tipografía no es sólo para especialistas y diseñadores gráficos, no es un producto nicho, sino un área en si misma, independiente, que puede ser más interesante de lo que parece a primera vista. Os enseñamos la fuerza y pasión de la tipografía. Los autores de Typostrate son Christian Goldemann y Michael Zeller. ¡Que disfrutéis leyendo!

    Jean Chardin: French Still Life Painter, Late Baroque #jean #chardin, #still #life #painter, #french #baroque


    Jean Chardin (1699-1779)

    The French painter Jean-Baptiste-Simeon Chardin is considered one of the finest exponents of still life painting in the history of art. Largely self-taught and influenced in particular by a down-to-earth realism. he produced highly polished small-scale works of still life as well as numerous examples of genre painting evoking a sober, simplistic harmony. Although both his background and his subjects were humble, he became one of the most important and influential contributors to French painting of the 18th century, raising still lifes and domestic scenes to a new level of importance. In particular, look out for his still-life arrangements of basic kitchen utensils and ordinary foodstuffs, as well as his domestic scenes featuring children and servants occupied in work and play – all based on direct observations and a natural style of painting, with no surprise effects or hidden meanings. His notable works include The Ray (1728, Louvre, Paris), Still Life with Ray-Fish and Basket of Onions (1731, North Carolina Museum of Art, Raleigh, NC), Boy with a Top (1735, Sao Paulo Museum of Art), The House of Cards (1736-7, NG, London), and Woman Cleaning Turnips (1738, Alte Pinakothek, Munich). Chardin remains one of the great Old Masters of the 18th century and one of the best still life painters of all time.

    Frans Snyders (1579-1657)
    Still life painter from Antwerp.
    Samuel van Hoogstraten (1627-78)
    Interiors, genre works, still lifes.
    Rachel Ruysch (1664-1750)
    Flower painter, still lifes.

    Early Life and Works

    Born in Paris, the son of a Cabinet-Maker, Chardin’s whole life was spent in Paris, between the Rue de Seine, where he was born, the Rue Princesse and the Rue du Four, where he lived in a number of places, and the Louvre, where he lived from 1757 until his death. He apprenticed under the history painters Pierre-Jacques Cazes and Noel-Nicholas Coypel. In his lessons he learned to draw from classical sculpture and from a model. However, his interest in observing nature closely and recording what he was doing soon became apparent. He produced his first still lifes in the 1720s, though it is difficult to know exactly when, since many of them are not dated. He chose simple, everyday objects, enjoying the variety of textures and shapes that even these ordinary items provided. He may also have been attempting to paint different subjects than those of the already established still-life painters, such as Jean-Baptiste Oudry (1686-1755), who depicted dead rabbits, partridges and other game. In 1724 Chardin became a master at the Academie de Saint-Luc (school for the guild of painters and sculptors).

    Member of the French Academy

    His first major painting, The Ray (a still life of various fish and a cat) was exhibited in 1728, and received a warm reception. On the basis of this work he became a member of the French Academy. where he was received as a painter of animals and fruits . This was considered the lowest kind of painting by the Academy, according to its Hierarchy of Genres. which preferred grand paintings with classical or historical significance. In fact history painting was deemed to be the highest form and still life the lowest. Nevertheless, Chardin’s output during this period was prolific, and several versions of his paintings exist, suggesting there was a good market for his still lifes, domestic interiors and genre paintings. Moreover, he remained a loyal member of the Academy: from 1737 onwards he exhibited regularly at the Salon (the exhibition held every year by the Academy) and served on the organising committee, becoming its treasurer in 1755.

    Still Lifes and Genre Paintings

    Chardin married in 1731, and began to receive commissions from rich patrons. As he became more successful, he decided to paint figures. He did not choose grand and historical subjects, but instead rather like his simple still-life subjects, depicted ordinary people, usually in domestic roles. These genre scenes became very popular with the viewers at the Paris Salon and Chardin soon had a rich international clientele. Less wealthy clients bought engravings of his work. In this way he reached an extremely wide public and became recognized as one of the best genre painters of the age. Following the death of his wife in 1735, he married a widow in 1744. In the 1750s he returned to painting still-lifes, both kitchen objects and also game subjects. Among his best-known still life pictures are: The Silver Goblet. (Louvre), The Silver Tureen (c.1728, Metropolitian Museum of Art, New York); The Meat Day Meal (c.1731, Louvre); A Lean Diet with Cooking Utensils (1731, Louvre); Pipes and Drinking Pitcher (1737, Louvre); Still-Life with Jar of Olives (1760, Staatliche Museum, Berlin) and Still-Life with Dead Pheasant and Hunting Bag (1760, Staatliche Museum). Chardin mainly used earthy tones in his work, and was a master of texture and the soft diffusion of light. Earlier masters of the genre included the Dutch artists David Bailly (1584-1657), Jan Davidsz de Heem (1606-83), Harmen van Steenwyck (1612-56), Pieter Claesz (1597-1660), Willem Kalf (1622-93) and Willem Claesz Heda (1594-1681).

    Chardin’s paintings of children were especially popular as they portrayed children in an innocent yet unsentimental manner. Among his greatest genre paintings are: The Young Schoolmistress (1736, National Gallery, London); The Soap Bubble (1739, Metropolitan Museum of Art); The Governess (1739, National Gallery of Canada) and The Prayer before Meal (1740,Louvre). His domestic scenes are almost poetic, and capture the most simple of daily tasks: a woman writing a letter, a man playing cards, a maid peeling vegetables. His themes show the influence of the Dutch Realist Jan Vermeer who had also painted similar peaceful interior scenes just fifty years previously. In a similar way, Chardin depicted a closed world, one that is frozen in time, displaying restful intimacy, childish pleasures and simple easy-to-understand symbolism. Important works in this area include: The Return from the Market (1739, Louvre); Girl with Racket and Shuttlecock (1740, Uffizi, Florence); Boy Playing with Cards (1740, Uffizi); Sending the Letter (1733, Schloss Charlottenburg, Berlin); The Draughtsman (1737,Staatliche Museum, Berlin); The Attentive Nurse (1738, National Gallery of Art, Washington DC); Girl Peeling Vegetables (Alte Pinokothek, Munich); The Canary (1750, Louvre) and Self-Portrait with Eyeshade. 1775 (Louvre). Another exceptional French genre painter of the 18th century was the highly popular Jean-Baptiste Greuze (1725-1805).

    Later Years and Legacy

    In 1752 Chardin was granted an annual salary by King Louis XV and went on to receive further stipends for his work in organising exhibitions at the Salon. A few years later, his eyesight began to weaken and he took to painting in pastels. In fact his Self-Portrait with Eyeshade was executed in this medium. Chardin s later life was marred by tragedy, when his son, also a painter, drowned in Venice. It is believed that he committed suicide. The artist’s last known oil painting was created in 1776, although he continued to paint and draw in pastels until his death, at the age of 80.

    Chardin’s influence on future generations has been well documented. The portrait of a Boy Blowing Bubbles by Edouard Manet and several still lifes by Paul Cezanne show a direct influence. The Fauvist painter Henri Matisse admired his work and copied several when he visited the Louvre. Many other famous painters, including the still life virtuoso Giorgio Morandi. and the portraitist Lucian Freud, cite Chardin’s work as an inspiration to their painting.

    Still lifes by Chardin can be seen in the best art museums across the world.

    For more about French still life painters, see: Homepage.


    Property Management Software – Easy Desktop Rental Property Software #tenant #file, #property #management #software, #rental


    The best property management software at an affordable one-time price!

    What is the Tenant File?

    A simple, powerful tool that landlords and property managers love.

    We’ve been working with landlords, rental property owners, and property managers for over 20 years.

    The Tenant File is easy to use, has powerful features, and your data is safe and easy to back up. You can use it on an office network and install it at both home and office at no extra charge. And, there is no unending subscription plan as in online software – the software is yours to keep for one very reasonable price. So, if you need on on-location or on-premise software, the Tenant Files is the best choice.

    Why choose desktop software?

    There are a lot of web based (or cloud) software products out there these days. But we think you should really consider if that is the best choice for your company.

    You are responsible for your tenant accounting and your owner’s private information. A desktop software offers better speed and security, plus the Tenant File still incorporates the Internet features that you need such as ACH transfers, emailing capabilities, and tenant screening.

    Recent intrusions into online privacy have shown that the valuable data you keep for your company, or on behalf of real estate investors may not be as safe as you might think. That is only one of many reasons why we think that the Tenant File desktop property management software is the best software for property managers and landlords.

    What do others think?

    PC Computing Magazine – ” It has the powerful features of many other higher priced software, but is one of the lowest priced products on the market.”

    George N Politis CPA After reviewing many Property Management software packages, I came to the conclusion that Tenant File is the best software that I can recommend to my clients in the real estate business. It is easy to use, flexible, it prints many reports especially the ones for your accountant at the end of the year. Few years ago I did some reviews for the CPA Software News. Thank you for a great software.

    Lindsey Rellot, Property Manager
    “Thank you for making a program that is user friendly”

    Excelsior College #nursing #college


    Please use this template on full width, 20-80 or 80-20 layouts only.

    Nursing Theory Completion Options

    The nursing theory series includes the 8 nursing requirements in Phase I and Phase II of the associate degree nursing curriculum. Phase I requirements must be completed before advancing to the second phase of the curriculum. Please be sure to access the School of Nursing catalog for nursing phasing requirements.*

    You have three options: Excelsior College nursing courses, Nursing Theory Conference Exams (NTCX), or Excelsior College Exams (ECE) to complete the nursing theory series. The options are interchangeable, therefore, you may select any and all options to complete the requirements.

    Next steps: Speak with a School of Nursing academic advisor. The academic advisor will assist with the following:

    • Determine if pre requisites have been satisfied to begin the nursing theory series.
    • Provide approval to register for an Excelsior College course, NTCX or ECE.
    • Provide direction as to next steps.

    * The phases are applied to students who enrolled on or after July 1, 2014.

    Associate Degree Nursing Theory Online Courses

    Students are provided a term-based experience facilitated by a faculty member. Students complete assignments, participate in weekly discussions with faculty and peers, and are tested on content through weekly quizzes and 2 comprehensive examinations. Students are expected to adhere to all deadlines and complete all work within the 8 week term.

    • Academic advisors provide approval for a selected term. Students must review the academic calendar for important deadline dates.
    • Courses are offered in an eight (8)-week term format. Visit the Course Search page to review the term in which each nursing course is available, the course description, and sample syllabi.
    • Students must purchase required textbooks prior to the start of the course.
    • The 8-week term is extremely rigorous. Each course requires 18 hours or more each week in preparation and participation.
    • Graded assignments include weekly discussions and quizzes and two comprehensive examinations.
    • Seating in online nursing courses is limited.
      • Students must plan ahead and review the academic calendar for important deadline dates.
      • Students who have received course approval prior to course registration opening for the upcoming trimester are placed on the course invitation list according to the number of nursing credits earned. The more nursing credits earned, the more likely a student receives an invitation to register.
      • The first invitations to register are sent through the Student Information System (SIS) messaging at 12:01 am (ET) on the day course registration opens. Registration must take place within 48 hours of the time stamp on the invitation or the invitation expires. No extensions on the registration window are granted.
    • Refer to the Student Policy Handbook. which outlines College policies and student responsibilities.
    • Visit the cost and financing page for current tuition costs.
    • Financial Aid
      • Students are eligible to apply for federal financial aid for online nursing courses.
      • If you plan to use financial aid, complete a Financial Aid Study Plan via MAPlanner well in advance of the first day of course registration. Students can submit their Financial Aid study plan once they have received nursing course approval and have a completed FAFSA on file.
      • Students must complete at least 6 credits of online courses and/or NTCXs per trimester to be eligible for financial aid.
      • The financial aid team requires 7-10 days to package an offer once the Financial Aid Study Plan is submitted.
      • If the Financial Aid package has not been accepted before course registration opens, another form of payment is requirement to secure a seat in the course. Reimbursement may be available if/when a Financial Aid package is offered.
      • Students should check My Message Center and email for alerts from the financial aid team regarding the status of the Financial Aid package and/or award letter.
      • Financial aid questions should be directed to the Excelsior College Financial Aid staff at 855-323-9235.

    Nursing Theory Conference Examinations (NTCX)

    Students are provided a term-based experience that combines facilitated preparation for a nursing theory ECE. The NTCX allows for an organized approach to examination preparation while retaining the flexibility of the independent learner.

    • Academic advisors provide approval for a selected term.
    • Each NTCX is offered in an 8-week term format. Visit the Course Search page and choose, under Department, Nursing (NURCX) to review the term in which each NTCX is available.
    • Students are expected to download and review the current content guide for the approved NTCX prior to the start of the term.
    • Students must purchase the required textbooks and have the majority of the required readings (noted in the content guide) completed prior to the start of the NTCX.
    • Expect to spend 10-12 hours per week on the NTCX. This assumes significant time was dedicated to studying and preparing for the exam prior to the beginning of the NTCX.
    • Participation includes completing the weekly discussion questions and self-check quizzes, and applying nursing knowledge to the case studies. Faculty feedback is provided.
    • Participation requirements must be met to receive the Authorization to Test (ATT) letter. The ATT letter allows you to schedule to take the ECE at the Pearson Vue Testing center. The ATT letter is sent approximately 2 weeks prior to the end of the term.
    • Students must schedule and take the ECE during week 8 of the term. Failure to schedule, show, or take the ECE examination by the end of the term results in students earning a grade of “F”.

    Refer to the Student Policy Handbook. which outlines College policies and student responsibilities.

    • Visit the cost and financing page for current tuition costs.
    • Financial Aid
      • Students are eligible to apply for federal financial aid for NTCXs.
      • If you plan to use financial aid, complete a Financial Aid Study Plan via MAPlanner well in advance of the first day of course registration. Students can submit their Financial Aid study plan once they have received NTCX approval and have a completed FAFSA on file.
      • Students must complete at least 6 credits of online courses and/or NTCXs per trimester to be eligible for financial aid.
      • The financial aid team requires 7-10 days to package an offer once the Financial Aid Study Plan is submitted.
      • If the Financial Aid package has not been accepted before course registration opens, another form of payment is required to secure a seat in the course. Reimbursement may be available if/when a Financial Aid package is offered.
      • Students should check My Message Center and email for alerts from the financial aid team regarding the status of the Financial Aid package and/or award letter.
      • Financial aid questions should be directed to the Excelsior College Financial Aid staff at 855-323-9235.

    Study independently and register for an Excelsior College Examination (ECE ) in Nursing Theory

    Students study and prepare independently to take a credit bearing examination. Students register to take the examination within a trimester.

    • Academic advisors provide approval for a trimester, therefore, it is important to request approval before the start of the trimester.
    • Students download the current content guide for the approved ECE and use the content guide to assist in preparing for the ECE. Students are expected to purchase the required textbooks and complete the assigned readings prior to taking the ECE.
    • Plan to spend 135 hours or more to prepare for each ECE.
    • Students register to take the ECE through exam registration .
    • Once registration is complete, student will receive an Authorization To Test (ATT) letter for the specified ECE.The ATT letter allows you to schedule to take the ECE at the PearsonVUE testing center.
    • You must schedule to take the ECE within the trimester in which you are registered.
    • Failure to schedule, show, or take the ECE examination by the end of the trimester in which you are registered results in earning a grade of “F”.

    Refer to the Student Policy Handbook. which outlines College policies and student responsibilities.

    • Visit the cost and financing page for current tuition costs.
    • Financial Aid: ECEs in nursing theory are not eligible for federal financial aid.

    Will Shading Your Air Conditioner Save You Money? #natural #gas #air #conditioner #vs #electric


    Will Shading Your Air Conditioner Save You Money?

    I got a question this weekend that’s often asked—and, I’m sure, wondered about—by homeowners: “Will my household AC system run more efficiently (perhaps cycle on/off fewer times, or the compressor won’t have to run as long when it cycles on) by shading the compressor?” I’ve written about the outdoor unit of air conditioners and heat pumps a few times, but I’ve never tackled this question directly. Let’s change that now.

    Why this is a natural question to ask

    First, a little explanation about air conditioners. That metal noisemaker that sits out in back or on the side of your house is called the condensing unit for air conditioners. The compressor is one component in that box, but the condensing coil and a few other parts are there, too. (To understand how an air conditioner works, see my article, The Magic of Cold .)

    The condensing coil’s job is to dump the heat picked up inside the home to the outdoor air. (If you have a ground source heat pump, that heat gets dumped into the ground rather than the air, and you won’t have an outdoor unit like the one shown above.) The hotter it is outdoors, the harder it is to dump that heat and the more you’ll spend keeping your house cool.

    Hence the question, can shading your air conditioner’s outdoor unit provide significant savings? And the answer is yes and no. It depends on what type of shading we’re talking about, but for the type of shading most people are thinking about when they ask that question, the answer is no.

    Why the answer is mostly no

    Shading the outdoor unit with a structure as shown below will reduce the direct solar gain from insolation but won’t do a whole lot for the air temperature around the unit. That photo is from a study done the Forida Solar Energy Center on the effectiveness of shading air conditioner condensing units.

    Caution: The unit below exhausts from the side so the shading structure doesn’t interrupt the air flow. Most AC outdoor units exhaust from the top and that structure would reduce the air flow and perhaps cause serious damage to the unit. Don’t try something like this unless you have a good understanding of air conditioners.

    In the Discussion section at the end of their report, the FSEC authors give the big reason why small scale shading like this doesn’t work. The temperature of the surrounding air has a much bigger effect on cooling efficiency than direct solar gain, and the volume of air pulled in by an air conditioner is huge.

    A typical 3 ton air conditioner condensing unit might pull in 2800 cubic feet per minute (cfm) of outdoor air. If it ran continuously for an hour, 168,000 cubic feet of outdoor air would move through the outdoor unit. Since your air conditioner is probably oversized, it won’t run the full 60 minutes. My oversized AC. for example, runs about 30 minutes an hour at design conditions. Even at 30 minutes per hour, though, the outdor unit pulls in 84,000 cubic feet of outdoor air.

    To put those numbers in perspective, 84,000 cubic feet is about three times the volume of a typical house being cooled by that 3 ton AC. It would take a lot of shading to cool that much air.

    The FSEC study sums it up this way:

    We conclude that any savings produced by localized AC condenser shading are quite modest ( 3%) and that the risk of interrupting air flow to the condenser may outweigh shading considerations. The preferred strategy may be a long-term one: locating AC condensers in an unobstructed location on the shaded north side of buildings and depending on extensive site and neighborhood-level landscaping to lower localized air temperatures.

    A related question to shading the condensing unit is about saving money by spraying a mist of water on the unit, especially with the recent launch of the Mistbox. I wrote about that topic a couple of weeks ago, and again, the answer is that you’re better off looking elsewhere.

    If you really want to improve the efficiency of your air conditioner, your opportunites are much greater if you look to your duct system. By fixing disconnected ducts. flacid flex. uninsulated boots. and more, you may be able to cut your air conditioning bill in half, depending on how bad your particular ducts are. And they most likely are bad.

    9 Uncommon Tips for Keeping Cool with a Struggling Air Conditioner

    Does a Heat Pump or Air Conditioner Condenser Need to Go Outdoors?

    An Easy Way to Save Money — Let Your Air Conditioner Breathe!

    Surprise! I’m an Air Conditioner Compressor Killer

    Is Evaporative Cooling the Answer to High Air Conditioning Costs?

    NOTE: Comments are moderated. Your comment will not appear below until approved.

    Zoom Blog – The Cloud Video Conferencing Company #video #conferencing #websites


    • I recommend Zoom to any company that wants a true business-grade collaboration platform. Leo Gomez AV Systems Engineer at SolarCity
    • Zoom is changing the way our global team members communicate. Dan Snodgrass Global Marketing Manager, JAS Forwarding Worldwide, Inc.

    Congrats on your first Zoom account! We hope you’re enjoying your glorious HD video meetings. It s possible though, that you haven t fully unlocked the power of Zoom. Here are a couple key tips that will help you make the most of Zoom! 1. Explore Zoom. Start a meeting, click around, try screen sharing, recording, annotating, [ ]

    So You’ve Got a Zoom Account…Now What?

    Today Zoom and Polycom jointly announced a new solution that gives customers more choices in how they collaborate by combining the benefits of Zoom’s cloud-based enterprise video communications with Polycom’s powerful video experiences. Zoom and Polycom customers can now experience the high-quality Zoom video meetings that everyone loves in rooms powered by Polycom’s award-winning video [ ]

    Partnership Announcement: Zoom Connector for Polycom

    Zoom loves Zendesk – it’s the backbone platform of our support team. Zendesk loves Zoom – it is their organization-wide communications solution. So we got together to create an awesome integration called Zoom For Zendesk, which will empower your customer success and support teams with instant Zoom meetings right from the Zendesk interface. Key Benefits [ ]

    Total Customer Zen with Zoom and Zendesk

    Happy Global Accessibility Awareness Day (GAAD)! On this day we raise awareness about online access and inclusion and people with disabilities. Part of this effort is to make web-based services and websites like Zoom easy to use for people with disabilities. In celebration of GAAD, this coming weekend Zoom will release a couple new features [ ]

    The Perfect Day for New Zoom Accessibility Features

    A face-to-face meeting can be 34 times more successful than an email according to a recent HBR article. Face-to-face meetings are always my preference when possible, but in reality it’s not always an option or an effective use of time. In sales, face-to-face meetings can be expensive, time consuming, and can seem like a large [ ]

    Sales Experts Share their Video Conferencing Tips

    The Zoom events schedule is heating-up next week with not one, but two big shows! Our events coordinator is wearing out the carpet at HQ and we are buzzing with excitement about Interop in Las Vegas, and our inaugural participation at UC Expo 2017 in London, which also marks our debut into the European show [ ]

    Zoom Jumps the Pond to UC Expo

    Next week Zoom is visiting fabulous Las Vegas for the annual Interop IXT Conference at the MGM Grand. Here’s what our fellow Interopers need to know to get some Zoom in their lives! The Zoom Booth Check out booth #329 for all things Zoom. We’ll be showing off Zoom Rooms for Touch on a Display [ ]

    Zoom Hops to Interop!

    Almost 6 years ago, I left Cisco WebEx with a core team of engineers to build Zoom. By August 2012, we had an early beta product: Zoom 0.9. It wasn t perfect, but it had promise. We were proud and couldn t wait to share it with the world. But in an industry crowded with giants, we [ ]

    Walt Mossberg: An Appreciation

    Check out our short video case study on the Phoenix Children s Hospital. This video features an interview with Rachel Dunagan, AV Technician for Phoenix Children s. Dunagan describes how Zoom has helped caregiving teams communicate, improving patient outcomes, all while decreasing technical support issues. For example, Phoenix Children s uses Zoom meetings with screen sharing to connect their [ ]

    Video Testimonial: Phoenix Children s Hospital

    Buying a car in Belgium #car #insurance #belgium


    Buying a car in Belgium

    While public transport in Belgium is excellent within and between cities, journeys to the suburbs and smaller towns are more easily accomplished by car. Having your own vehicle will save a lot of time on the commute and allow for greater exploration of Belgium’s less accessible regions.

    Since both the new and second-hand car markets in Belgium are well-regulated, offering much protection to consumers, and prices are competitive compared with neighbouring countries, buying a car here can be a worthy investment.

    New cars are sold at a variety of dealerships across the country, selling many of the globally recognised leading brands. For reviews, check out Auto Magazine. Second-hand cars may also be found at professional dealers, although private sales are common in Belgium. Among the largest of the car dealerships are D’Ieteren, Cegeac, Cardoen and NNC. Many private sales are advertised on recognised websites (see box below).

    Be it a new car or a second-hand car, there are several documents that must be provided by the seller, including a document detailing the car’s characteristics, the price, delivery date, any agreed reductions, underwriting of credit and any amount offered in part-exchange.

    The seller must also provide a certificate of conformity (certificat de conformité ), a log-book for the vehicle (carnet d’entretien ) and a so-called pink form (formulaire rose ), required for the registration (immatriculation ) of the vehicle.

    In Belgium, registration is required in almost all cases for residents and can be made online with the Vehicle Registration Service (DIV). The only exceptions are for cars registered abroad and offered by a foreign employer or international institution in another EU member state for use in Belgium.

    In the case of second-hand cars, sellers, whether professional or private, must also provide a certificate proving that the vehicle has undergone a technical examination (controle technique /autokeuring ) within the last two months. Private sales are often cheaper, especially if you pay cash in hand.

    The buyer receives, together with the certificate, a report on the condition of the second-hand car (rapport d’occasion ), which provides full details on the results of the technical examination and detail of any faults with the vehicle.

    Finally, the seller is obliged to provide a Car Pass, a certificate of the number of kilometres a car has travelled. Buyers are advised by Car Pass to check that the certificate matches the odometer, which should also increase at a steady rate.

    Before you buy, it’s worth considering whether your employer will offer you a company car. This is common practice in Belgium and the European Commission estimates that only 30 percent of journeys made with company cars are for professional purposes.

    It is also worth considering whether to buy an eco-friendly model since there are many deductions available, including a substantial cut on the on-the-road tax (taxe de mise en circulation ). Vendors are also obliged to cut the price on low-emission models by as much as 15 percent.

    The government, conscious of the large volumes of traffic on Belgian roads and the consequent emission levels, has recently published a comprehensive guide (in Dutch and French) on the environmental credentials of leading brands.

    Photographers insurance – liability & equipment #photographers #liability #insurance


    Insurance for photographers

    What insurance do photographers need?

    Public liability insurance for photographers

    Public liability insurance is often very important for photographers as it can protect you if you’re blamed for injury to a member of the public or damage to their possessions. Imagine you’re doing a shoot and leave your tripod lying around on set when you take a break. If someone trips over your equipment and injures themselves, they could make a compensation claim against you.

    Compensation payments can take into account costs like medical bills and loss of income, so they can be high. Also, if you’re found liable you usually have to pay the legal expenses for the other side as well as your own legal costs. We offer £1 million to £10 million of public liability insurance to cover these costs, and when choosing a cover level you should check your client contracts to see if they require a particular level of insurance.

    Professional indemnity insurance for photographers

    Professional indemnity insurance is another key consideration for photographers, especially if you photograph important events like weddings or public occasions. For example if you’re hired to photograph a wedding but your memory card is corrupted and all the photos from the day are lost, the couple could sue you for failing to deliver the photographs. Your professional indemnity insurance could step in to pay the legal costs and compensation payments, up to the limit of your policy. You can buy professional indemnity insurance as a stand-alone cover or as part of a combined policy with other insurance. At Simply Business we offer between £50,000 and £5 million in professional indemnity cover.

    Insurance requirements for photographers

    Check the requirements set by your professional bodies – The British Institute of Professional Photography and the Master Photographers Association both require their members to have public liability and professional indemnity cover.

    Find out what level of professional indemnity insurance your clients might expect before you buy.

    Photographers’ equipment insurance

    Since your cameras, lenses and accessories are crucial for your work, it’s a good idea to cover them too by adding business equipment insurance to your photographers’ insurance policy. This cover can pay to replace or repair your equipment if it’s damaged or stolen, up to the limit of your policy. Make sure you calculate the value of your photography equipment as accurately as possible so that you’re fully covered if you come to make a claim.

    Other business insurance for photographers

    If you have any employees, then you’re usually legally required to have employers’ liability insurance. and you can face severe penalties if you don’t have a policy in place. You could also consider other covers including legal expenses insurance. business interruption cover and business buildings and contents insurance, depending on what your business needs.

    Need more details? Hear more about your business cover options from our expert team in a quick set of videos. Just choose the cover you’re interested in and get some expert insight into how each option can help your business. You can also check out our business insurance FAQs .

    Redox Flow Batteries 2017-2027: Markets, Trends, Applications: IDTechEx #research,idtechex,rfid,smart #labels,printed #electronics,smart #packaging,frequency,case #studies,healthcare,active #rfid,food #traceability,retail,walmart,antenna,chipless


    Energy Storage Report

    Redox Flow Batteries were initially developed by NASA in the 70’s for its space programme. The expiry of a number of patents related to RFBs in 2006 has sparked an industrial race to commercialisation, which will grow to become a $4bn market by 2027.

    Often perceived as an underdog, redox flow batteries (RFB) may not deliver the same power of a Li-ion battery, but they can compete in terms of cycle life, safety, and reliability for stationary applications. Utilities around the world are avidly testing RFBs in pilot projects, while China is underway in the construction of the largest battery in the world (200 MW / 800 MWh), which will be entirely powered by redox flow batteries. If successful, this project will be replicated across the country and probably also in Europe and the US.

    In this report, technology analyst Dr. Lorenzo Grande from IDTechEx analyses the different flow battery chemistries available from a technology standpoint (all-vanadium, all-iron, zinc/bromine, hydrogen/bromine, polysulphide, etc.) as well as by engaging with the world’s main stakeholders (UET, Sumitomo, Primus Power, Gildemeister – just to name a few). Overall, 19 companies are included in this report, covering the whole RFB spectrum as well as all the main markets, namely USA, Europe, and Asia. The companies are compared in terms of their target markets and a series of case studies explains who are the most likely winners and why.

    RFBs operate by means of electro-active chemicals dissolved in liquid solutions that are named anolyte and catholyte, and which are stored into tanks. By exchanging ions through a membrane, it is possible to generate a cell voltage and extract energy out of such a system. The possibility to modulate both the tank and the membrane size independently allows for the decoupling of power and energy capabilities, thus making this technology extremely flexible and tailored to user needs.

    Stationary energy storage is a cost-effective way to increase renewable energy utilisation, as well as to implement energy efficiency measures, both at residential, industrial, and grid level. The redox flow battery technology, despite higher upfront costs and lower energy density, has a shorter payback time thanks to a good capacity retention even after many thousands of cycles. Additionally, redox flow batteries (RFBs) retain most of their initial value thanks to the possibility to recycle their core components more easily than other battery chemistries. Some RFB chemistries, like that based on vanadium, are already commercial and set to capture most of the $4bn market value. Other chemistries, like zinc/bromine and hydrogen/bromine, have the potential to capture significant portions of the market thanks to high-profile collaborations and partnerships already in place.

    Lithium-ion batteries will suffer a setback from the emergence of utility-grade flow batteries, which will contribute to ease the pressure on lithium resources that are more needed for electric mobility applications. One final interesting remark is that, with notable exceptions, a sizeable portion of the RFB industry is located in Europe and the US. The success of said companies will fuel the Western World’s competitiveness against the Asian Li-ion incumbents.

    Analyst access from IDTechEx

    All report purchases include up to 30 minutes telephone time with an expert analyst who will help you link key findings in the report to the business issues you’re addressing. This needs to be used within three months of purchasing the report.

    Americas (US): +1 617 577 7890

    Europe (UK): +44 (0)1223 812300

    Korea: +82 31 263 7890

    IRS Federal Tax Lien – Request a Payoff on your IRS Federal Tax Lien –


    IRS Federal Tax Lien Request a Payoff on your IRS Federal Tax Lien Former IRS Agents

    IRS Federal Tax Lien Request a Payoff on your IRS Federal Tax Lien Former IRS Agents

    Fresh Start Tax 1-866-700-1040 Former IRS Agents Tax Attorneys CPA s Enrolled IRS Agents Audit proof your tax returns

    Payoff Amount of the Federal Tax Lien

    The full amount of your lien will remain a matter of public record until it is paid in full, including all accruals and additions. However, at any time you may request an updated lien payoff amount to show the remaining balance due by calling the toll-free customer service telephone number at 1-800-913-6050. An IRS employee will issue you a letter with the current amount that must be paid before release of the Notice of Federal Tax Lien will be made.

    • Our staff has over 110 years of professional tax representation experience collectively
    • On staff, Board Certified Tax Attorney s, Certified Public Accountants, Enrolled Agents, Former IRS Manager, Instructor and Trainers
    • Highest Rating by the Better Business Bureau A
    • Extremely ethical and moral principles used
    • Fast, affordable, and economical
    • Licensed to practice in all 50 States
    • Premium on client communication
    • Nationally Recognized Veteran Former IRS Agent
    • Nationally Recognized Published Tax Expert

    Fresh Start Tax is one of the premier tax resolutions firms in the country. We deal with all types of civil cases including individuals, businesses, corporate and defunct corporations. We have staff that specializes in every facet of the Internal Revenue Service. We know all the IRS strategies. Some of our many specialties include the following:

    • Immediate Tax Representation
    • Offers in Compromise/Settlements
    • Back Tax Relief
    • Bank Garnishments or Tax Levies
    • Wages Garnishments or Levies
    • IRS Notices of Intent to Levy or Final Notices
    • IRS Tax Audits
    • Hardships Cases, Payment Plans
    • Innocent Spouse
    • Abatement of Penalties and Interest
    • State Sales Tax Cases
    • Trust Fund Penalty Cases/ 6672

    Dorothy B. Murphy

    I work for a title company and my Seller has a federal tax lien; he would like me to request a payoff statement for him; what form should he sign. I am not an attorney or accounting just the escrow officer of a title company

    Call 866.700.1040 We Can Solve Your Tax Problem Immediately!

    Disclaimer: No Rendering of Advice – The information contained within this website is provided for informational purposes only and is not intended to
    substitute for obtaining accounting, tax, or financial advice from a professional accountant. Presentation of the information via the Internet is not intended
    to create, and receipt does not constitute, an accountant-client relationship. Internet subscribers, users and online readers are advised not to act upon this
    information without seeking the service of a professional accountant. Any U.S. federal tax advice contained in this website is not intended to be used for
    the purpose of avoiding penalties under U.S. federal tax law.

    Accuracy of Information – While we use reasonable efforts to furnish accurate and up-to-date information, we do not warrant that any information
    contained in or made available through this website is accurate, complete, reliable, current or error-free. We assume no liability or responsibility for any
    errors or omissions in the content of this website or such other materials or communications. Call Fresh Start Tax at 954-492-0088.

    Disclaimer of Warranties and Limitations of Liability – This website is provided on an “as is” and “as available” basis. Use of this website is at your own risk.
    We and our suppliers disclaim all warranties. Neither we nor our suppliers shall be liable for any damages of any kind with the use of this website.

    Links to Third Party Websites – For your convenience, this website may contain hyperlinks to websites and servers maintained by third parties. We do not
    control, evaluate, endorse or guarantee content found in those sites. We do not assume any responsibility or liability for the actions, products, services and
    content of these sites or the parties that operate them. Your use of such sites is entirely at your own risk.

    Frank Andreacchi, Ed Vecchio and Scott Szaro are no longer with the company and are pictured on our site.

    *Mr. Sullivan has been in private practice since 1982 in South Florida which gave roots to Fresh Start Tax LLC.
    The firm began as Sullivan & Powell PA and through the years transitioned to its now current form.

    2017 Fresh Start Tax. All Rights Reserved. 866.700.1040

    How to Clean a Flooded Basement #flooded #basement #cleanup


    How to Clean a Flooded Basement How to Clean a Flooded Basement

    Unfortunately, finished and unfinished basements are prone to flooding for various reasons. Sometimes the storm gutters and downspouts are clogged or plagued with holes and the water flows over them and down to the perimeter of the house rather than to the corners and away from the house.

    In some cases, the water table is located high in the ground. Once the ground becomes saturated and it continues to rain, the rain needs to find somewhere to go. Typically, it will overflow to the surface of the lawn or yard. However, if any cracks exist in the foundation of your home, the water is going to find entrance there.

    Many people are already aware that their home has this problem and have opted for the installation of a sump pump to remedy the situation. However, if your home is only now undergoing settlement and settlement cracks or experiencing stress fractures in its foundation, then you may wind up with a flooded basement before you know that you have a problem.

    Choosing Your Equipment

    Once you have discovered that your basement is undergoing a flood, the first step is to remove the water. If the flooding is minor, then all you need to do is mop the wet areas up with a mop or old towels. However, if the flooding is major, it s time to bring out the big weapons.

    If you don t have one of the following: portable sump pump, wet vacuum, or wet shop vacuum, go to the store and purchase one or see if you can borrow one from someone that you know. Additionally, places are available where you can rent these. Look in your local telephone book for contact information if you decide to rent the equipment.

    You need to consider a few things when determining which equipment you are going to use. The sump pump will require an outlet for the water to be removed. Realize that if your basement is flooding, then the existing drains in your basement may be inaccessible for draining purposes. You will probable need to obtain a long hose to attach to the sump pump so that you can hang it out the window and as far away from the home as possible.

    If you select the wet vacuum, realize that it will only be a matter of minutes before you have to empty the holding receptacle. The wet shop vacuum will hold more water, but it will be heavier and more difficult to empty, especially if you are trying to empty the water outside of the home. Make your decision wisely.

    Removing the Water

    Once you have the equipment that you need, begin to remove the water. The best place to begin is most likely the area that is going to sustain the most damage if the water sits. Another option is to begin on the highest section of the room where the water is the lowest and work your way in to the larger pools of water.

    Drying the Area

    If the rain has stopped, open the windows to allow moisture in the air to escape. This will help with the drying out process. Once the water has been removed from the floor of the basement, it is time to begin drying the area as completely as possible ass quickly as possible.

    If your heating system has not been affected by the flooding, turn the heat to a higher setting to help with the drying out process. However, remember to open the windows to allow the moisture in the air to escape. Using heat will evaporate the water into the air and the air will become humid and dense with moisture.

    Consider using fans to circulate the air and speed up the drying process. Place the fans in such a way that the air is blown away and out rather than into the room. This will help to prevent the growth of mild and mildew.

    Another option to speed up the drying out process is to use a dehumidifier. It s important to close the windows and doors when using a dehumidifier so that it works properly. Keep an eye on the dehumidifier s holding container and empty it as frequently as is necessary. Once the dehumidifier no longer extracts any moisture from the room, place it in another area of the basement and begin again.

    You may need to call in a professional if your heating system sustained water damage. Most likely, your homeowner s policy requires that it be cleaned by a professional prior to operating it again.

    Entry-Level Master of Science in Nursing Admission Information #entry #level #msn #programs


    Entry-Level Master of Science in Nursing Admission Information

    Case Management

    Case Management has a broad scope of practice and will allow you to experience nursing in a variety of settings and facilities. Graduates can practice as case managers emphasizing service to the patient, provider, or payer. Strong advocacy, decision making, and planning skills are necessary for graduates to function in increasingly complex roles within the rapidly changing health care system.

    The program requires two calendar years plus one semester (7 total semesters, including summer terms) for a total of 93 semester units. Upon completion of the first four semesters, students are eligible to take the RN licensure examination (NCLEX).

    Family Nurse Practitioner

    Nurse practitioners work in a variety of clinical settings, including outpatient clinics, ambulatory care settings, emergency departments, inpatient units, community health agencies, and private practice settings as co-owners and operators with other nurse practitioners, physicians, and other healthcare providers.

    The program requires three calendar years plus one semester (10 total semesters, including summer terms) for a total of 109 semester units. Upon completion of the first four semesters, students are eligible to take the RN licensure examination (NCLEX).

    Scholarships for Disadvantaged FNP Students

    In July 2016, Samuel Merritt University (SMU) was awarded $7.8 million in scholarship money for disadvantaged students who will join the University’s mission to diversify the healthcare workforce and improve outcomes in underserved communities. The federal assistance, known as the Scholarship for Disadvantaged Students (SDS) program. will be available to students from economically and educationally disadvantaged backgrounds. Under this program, the University will award up to $30,000 per year to each recipient, depending on need. New and continuing students are eligible to receive this scholarship. Awards are made automatically based upon information provided in the application for admission and on the FAFSA.


    Questions about the ELMSN Programs can be directed to the following Admission Counselors:

    Homepage – Duxton Asset Management #csam #asset #management


    This website is directed at accredited investors and institutional investors only (as defined in the Securities and Futures Act, Chapter 289 of Singapore), and in using this website the user warrants that they qualify as such in their relevant jurisdictions.

    This website contains information on investments and the dissemination of this information may be subject to or restricted by laws and regulations in particular jurisdictions. Information from this website is not intended to be published or made available to any person in any jurisdiction where prohibited by laws or regulations and must not be used in any way that would be contrary to local laws or regulations. Specifically, the products and services mentioned on this website must not be promoted in any jurisdiction where this would not be permitted. It is the responsibility of any persons who access the information contained in this website to observe all applicable laws and regulations of such jurisdiction. For the avoidance of doubt, this website is not directed at US persons.

    The content of this website is for information purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any shares or units in any of the funds referred to herein, in any jurisdiction to any person. Where an offer document is current, applications may only be made on an Application Form for the relevant funds, which will be available on request to investors fulfilling the relevant criteria.

    This website provides general information only and should not be regarded as investment, tax, legal or any other form of advice. Prior to making any investment decision it is recommended that you seek advice on whether the information is appropriate to your needs, financial circumstances and investment objectives.

    Users should be aware of the risks associated with equity investments. Please be reminded that past performance is not a guide to future performance, the value of investments and the income from them may go down as well as up and you may not get back the amount you invested, and rates of currency exchange may cause the value of investments to go up or down.

    All content included in this website including, but not limited to, text, graphics, photographs, images, video and audio clips, sounds, materials and reports, is protected under the intellectual property laws (including but not limited to the law of copyright) of Singapore and/or other applicable jurisidictions. Users of this website may not (i) republish, reproduce (including electronic reproduction by “uploading” or “downloading”), copy, distribute, publish, display, broadcast, modify, create derivative works or transmit (in any form or by any means) any such content in any manner, and (ii) in any way exploit any part of such content, in whole or in part, without the prior written consent of Duxton Asset Management Pte Ltd. Any unauthorized downloading, re-transmission, or other copying or modification of trademarks or other contents of this website may be a violation of statutory or common law rights which could subject the violator to legal action.

    The website is provided on an “as is” basis and Duxton Asset Management Pte Ltd does not represent or warrant that the information accessible via this website is accurate, complete, current, secure or that it will be free from viruses or other harmful elements. Neither Duxton Asset Management Pte Ltd nor any of its affiliates, directors, employees or other representatives will be liable for any damages, losses or liabilities of any kind arising out of or in connection with the use of this website.

    This website is not to be published, circulated, reproduced or distributed in whole or in part without the written consent of Duxton Asset Management Pte Ltd. The information on this website is subject to change without prior notice.

    Where this website contains links to other websites, Duxton Asset Management Pte Ltd does not make any representations nor does it endorse the information contained on third party websites.

    Special Notice to Persons in the United Kingdom

    In relation to persons in the United Kingdom, the information contained in the website is directed only at persons who fall within the following articles of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (FPO) as amended from time to time:

    1. Article 19(5) Investment Professionals

    2. Article 49(2)(a) to (d) High Net Worth Companies, Unincorporated Associations etc.

    or are persons to whom this website may otherwise lawfully be directed (the latter persons and all of the persons in 1 to 2 being together referred to as relevant persons ).

    The website must not be acted on or relied on by persons in the United Kingdom who are not relevant persons. Any investment or investment activity to which the website relates is available in the United Kingdom only to relevant persons and Duxton Asset Management Pte Ltd will only engage with relevant persons in accordance with the requirements of the FPO as amended from time to time.

    By accessing or using this website you agree to be bound by the above terms and conditions. This disclaimer and your use of the website shall be governed by and construed in accordance with Singapore law.

    © 2012. All Rights Reserved.

    • Home
    • Agriculture
      • The Megatrend
      • The Duxton Approach
      • Our Offering and Products
      • Agriculture Commentary
      • DALF Reports
      • Consultant Advisory
    • Water
    • Emerging Markets
      • The Megatrend
      • The Duxton Approach
      • Our Offering and Products
      • Emerging Markets Commentary
      • Consultant Advisory
    • SRI
    • Team
      • Singapore
      • Australia
      • Germany
    • Contact
      • Careers
      • Duxton Asset Management Singapore
      • Duxton Capital (Australia) Pty Ltd
      • Duxton Capital Advisors Germany

    Agriculture Focus

    Emerging Markets

    Private Equity

    Professional & Ethical

    Welcome to Duxton Asset Management

    Spun-out from one of the world’s foremost financial institutions, Duxton has established itself as a leading international and boutique asset manager with a dual focus.

    Agriculture and Asian Emerging Markets

    Duxton manages or advises assets of approximately US $700 million, of which US $460 million comprises agricultural investments. Duxton has operating investments on five continents and is currently working on live projects in Latin America, Australia, the Pacific, the Caribbean and Africa for its existing client base.

    Duxton is one of the leading international players in agricultural investments and one of the very few with a global direct investment footprint and track record. We manage or advise 21 operations that span 540,000 hectares of farmland and over 30 commodities, managed by approximately 500 on-the-ground senior farmers and supported by more than 13,000 farm workers, giving us breadth of experience and insight into this expanding market.

    Duxton stands out for its in-depth understanding of local markets and by leveraging its global reach to transfer technology and proficiency across its operations. Duxton offers an outstanding combination of a deep industry expertise, operational improvement skills and financial restructuring knowledge.

    Our clients include:

    • Institutional Investors, amongst them leading global pension funds, sovereign wealth funds, insurance companies and asset managers
    • Family Offices, both single and multi
    • Private Banks
    • Ultra High Net Worth Individuals

    Duxton is the investment manager of the Vietnam Phoenix Fund Limited (previously known as the DWS Vietnam Fund) and the Global Agricultural Land Opportunities Fund Limited (also previously under the DWS brand name).

    Duxton is regulated by the Monetary Authority of Singapore and has offices in Singapore, Australia and Germany.

    Latest News


    Contact Us

    Pharmacia – Lonely Planet #drug #research #companies




    Students bashing out rhythms, pot-smoking hippies, stroller-pushing parents and loved-up couples all meet at this precipitous viewpoint.

    This funicular has been creaking arthritically up the steep, narrow Rua da Bica de Duarte Belo since 1892. Jump aboard to save your legs.

    Great views, winning cocktails and a festive crowd make Noobai a popular draw for a sundowner at Miradouro de Santa Catarina. The vibe.

    Take a number (like at the deli counter) and prepare to wait at this Bica newcomer, a trendy and tasty maritime-themed hotspot dishing.

    Boehringer Ingelheim – sales performance, data and rankings – Top Pharma List #archimedes #pharma

    #boehringer pharmaceuticals


    Boehringer Ingelheim

    Data by GlobalData

    GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

    To find out more about how our research and consulting solutions can help you, please visit

    Featured jobs

    Director, Scientific Services Great salary and benefits
    ID Search Selection

    Director, Scientific Services 80 – 100,000 or more according to skills and experience + benefits
    Media Contacts (Recruitment Consu.

    Our higher purpose is to deliver better communication to increase and speed up the ability of patients to access better.

    Slide Deck: Kinetic: A new approach shaping the future of advisory boards How many times have we attended meetings that have little direction, or no clear objectives and left feeling disinterested and disengaged? Our “Kinetic” consulting approach is set to change all.

    Alzheimer’s disease: reviewing the immediate treatment horizon Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer’s disease.

    Anthill awarded full Veeva certification We are proud to announce we have been certified level 4 Veeva multichannel content partner.

    Quick links


    File: Pharmacia – Wikimedia Commons #pharma #industry #news



    File:Pharmacia Popular.jpg

    You are free:

    • to share – to copy, distribute and transmit the work
    • to remix – to adapt the work

    Under the following conditions:

    • attribution – You must attribute the work in the manner specified by the author or licensor (but not in any way that suggests that they endorse you or your use of the work).
    • share alike – If you alter, transform, or build upon this work, you may distribute the resulting work only under the same or similar license to this one. CC BY-SA 3.0 Creative Commons Attribution-Share Alike 3.0 true true

    File history

    There are no pages that link to this file.


    This file contains additional information, such as Exif metadata, probably added from the digital camera or scanner used to create or digitize it. If the file has been modified from its original state, some details may not fully reflect the modified file. The timestamp is only as accurate as the clock in the camera, and it may be completely wrong.


    Sun Pharmaceutical Sdn Bhd #avema #pharma #solutions

    #sun pharma products


    Welcome to Sun Pharmaceutical

    Find out more about our products in heart management, skin and hair management, pain management, microcirculation management, energy power, mental performance, bone & muscle management and our reproduction function medicine product line. Sun Pharmaceutical is driven by a strong set of core values and work ethics, people-centric and conducts a variety of community-based public forums and education campaigns as part of our CSR (Corporate Social Responsibility). We also conduct some R D (research and development) activities and hosts medical talks and seminars.

    Research Development

    Copyright � 2011 – 2013 Sun Pharmaceutical Sdn Bhd. All Rights Reserved.

    To establish Sun as the most valued pharmaceutical sales & marketing distribution company in ASEAN while maintaining our uncompromising values as we grow through innovative products, knowledge services, people development and business best-practices.

    Sun Pharmaceutical Sdn Bhd Warning!
    /* 728×90, создано 05.02.11 */
    google_ad_slot = “6127977750”;
    google_ad_width = 670;
    google_ad_height = 90;

    Pharmaceutical companies jobs #pharma #management

    #pharmaceutical companies jobs


    278BioTech / Pharmaceuticalindustry jobs

    • West
    • Login to view salary
    • Responsibilities: Provide support for finance activities: closing, balance sheet. Responsible to maintain and reconcile general ledger. Review and perform monthly amortization of prepayment on monthly basis prior to month-end close. Assist in preparation of statutory and taxation schedules and.

    Associate Engineer (MNC / Pharmaceutical / East / 5D / Up $3.5k / GMP / Gxp Doc / )

    • East (Singapore)
    • Login to view salary
    • Our Clients A fast growing and leading pharmaceutical company of high establishment is undergoing expansion plans in the region to support the.
    • West
    • Login to view salary
    • Responsibilities: Carry out analytical testing on Finished Products and Raw Materials to support production activities, and the needs of other departments/sections such as A TG, Material Management, Procurement, and E M and to ensure timely release of FP and RM. Investigates and documents.

    Engineer, Automation

    • Global healthcare leader that offers career growth opportunities
    • Positive and collaborative work environment
    • A shared purpose in saving and improving lives around the world
    • West
    • Login to view salary
    • Under the supervision of the IPT Automation Lead, Automation Engineer is responsible for providing technical support in the field of automation.

    Medical Officer

    • West
    • Login to view salary
    • Job Summary Perform Medical Monitoring (Assess feasibility, give scientific input from start up through to close out, review protocols). Maintain.

    Medical Sales Executive

    • East
    • Login to view salary
    • Responsibilities Promoting and selling Traditional Chinese Medicine (TCM) products to Chinese medicine clinics and medical halls. Contact new or.

    Sr Software Engineer (Bioinformatics) – (5846BR)

    • Singapore – Singapore
    • Do you want to make a difference? Illumina’s mission is to improve human health by unlocking the power of the genome. If that inspires you, let’s.

    Organizational Learning Executive

    • West
    • Login to view salary
    • Responsibilities: Address training needs (functional skills and development training) Conduct Annual Training Needs Analysis with business partner to determine departmental training requirements to meet business needs. Monitor departmental training status with individual leaders on regular basis.
    • West
    • Login to view salary
    • Responsibilities: Perform studies to identify and improve existing process efficiency. Conduct process validation in coordination with Technical Services, QA, E M and other departments. Monitor and report indicator of process performance. To lead in motivating and reinforcing expected.

    Facility Security Maintenance Specialist – MNC (Medical) / North / S$2.5K to $3.1K

    • North
    • Login to view salary
    • US MNC (Medical) / North/Up to S$3.1K
      Familiar with preventive and corrective maintenance for all Security systems -CCTV, Card Access System, Door Alarm System, and etc
      12 month renewable contract
      Experience in Manufacturing Industry preferred
      Our client.

    Senior / Automation Engineer – Life Science MNC

    • East
    • Login to view salary
    • Strong hands-on experience in equipment, Jigs Fixture Factory automation and medical equipment design experience preferred.
      Opportunity to be stationed in US Plant (6- 18 months) for product transfer training
      Singaporean only
      Our client, a US Life Science.

    Quality Engineer-Software Validation (US Biomedical Manufacturing)

    • East
    • Login to view salary
    • Responsibilities: Responsible to assure that manufacturing processes comply with the product specification and regulatory government agencies requirements. Provide mechanisms for controlling the total quality and establish ways of evaluating the quality of our products. Responsible to develop.